AU2004215674B2 - Method for producing the enantiomeric forms of cis 1,3-cyclohexanediol derivatives - Google Patents

Method for producing the enantiomeric forms of cis 1,3-cyclohexanediol derivatives Download PDF

Info

Publication number
AU2004215674B2
AU2004215674B2 AU2004215674A AU2004215674A AU2004215674B2 AU 2004215674 B2 AU2004215674 B2 AU 2004215674B2 AU 2004215674 A AU2004215674 A AU 2004215674A AU 2004215674 A AU2004215674 A AU 2004215674A AU 2004215674 B2 AU2004215674 B2 AU 2004215674B2
Authority
AU
Australia
Prior art keywords
alkyl
formula
alk
cis
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004215674A
Other versions
AU2004215674A1 (en
Inventor
Wolfgang Holla
Stefanie Keil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2004215674A1 publication Critical patent/AU2004215674A1/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request for Assignment Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Application granted granted Critical
Publication of AU2004215674B2 publication Critical patent/AU2004215674B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Description

WO 2004/076390 PCT/EP2004/001580 1 Description Method for producing the enantiomeric forms of cis 1,3-cyclohexanediol 5 derivatives The invention relates to a process for preparing chiral, nonracemic, cis configured 1,3-disubstituted cyclohexanols of the formula (1) R1 R (I) 10 Variously substituted, cis-configured 1,3-disubstituted cyclohexane derivatives (compounds of the formula (1) where R 1 R 2) are central building blocks or precursors of the active pharmaceutical ingredients 15 which are described in WO 03/020269 and are generally suitable for treating lipid metabolism disorders, type I diabetes and syndrome X, inter alia. The syntheses which are described in the patent application 03/020269 of 20 the nonracemic, cis-configured 1,3-cyclohexane derivatives cannot be considered as industrial processes: for example, alkylations with NaH/DMF on the multi-kg scale cannot be carried out safely (C&EN, September 13, 1982, 5). Moreover, the alkylation by the Bu2SnO method on the industrial scale entails unacceptably high cost and inconvenience; the removal of the 25 tin compounds from the desired products is very difficult and usually incomplete even when chromatographic separating methods are used. The disposal of the tin compounds is a further problem and a cost factor. The separation of the enantiomers (optical resolution) by chromatography on a chiral phase is likewise inconvenient and too expensive. In addition, it is 30 necessary for chromatographic enantiomer resolution that the racemic compound is present in good chemical purity, which can be achieved in many cases by additional, preceding chromatography.
2 Other methods which have been described in literature for synthesizing cis 1,3-cyclohexanediol building blocks or derivatives, for example the opening of epoxycyclohexanes (P. Crotti, V. Di Bussolo, L. Favero, M. Pineschi, F. Marianucci, G. Renzi, G. Amici, G. Roselli, Tetrahedron 2000, 56, 7513 5 7524 and cit. lit.) or the metallized-catalyzed hydroboration of cyclohexene derivatives (J.A. Brinkmann, T.T. Nguyen, J.R. Sowa, Jr., Org. Lett. 2000, 2, 981-983; C.E. Garrett, G.C. Fu, J. Org. Chem. 1998, 63, 1370-1371) are predominantly unsatisfactory with regard to the regioselectivity and the stereoselectivity. The total number of stages is additionally distinctly higher. 10 They cannot be considered as industrial processes. The synthesis of cis-1,3-cyclohexanediol derivatives starting from cis,cis 1,3,5-cyclohexanetriol or cis,cis-1,3,5-cyclohexanetriol derivatives (L. Dumortier, M. Carda, J. Van der Eycken, G. Snatzke, M. Vandewalle, Tetrahedron: Asymmetry 1991, 2, 789-792; H. Suemune, K. Matsuno, 15 M. Uchida, K. Sakai, Tetrahedron: Asymmetry 1992, 3, 297-306) are likewise very complicated and uneconomic as a consequence of the high number of stages and therefore unsuitable for industrial use. The enzymatic reaction of the cis/trans mixture of 1,3-cyclohexanediol with S ethyl thiooctanoate cannot be considered as an industrial process. Apart 20 from the odor nuisance which can barely be avoided when working with the sulfur compounds and the fact that to achieve the required conversion, the ethanethiol which is released has to be removed continuously, the reaction described leads to a mixture of 9 isomeric forms or derivatives of cyclohexanediol, i.e. the unconverted isomers (S,S)-diol, (R,R)-diol and 25 (R,S)-diol, also the monoacylated products (S,S)-monooctanoate, (R,R) monooctanoate and (R,S)-monooctanoate, and thirdly the group of the diacylated products (S,S)-dioctanoate, (R,R)-dioctanoate and (R,S) dioctanoate. The optically active, monoacylated, cis-configured (R,S) monooctanoate takes up only a proportion of about 12% in the fraction of 30 the monoacylated cyclohexanediols. A preparation and isolation of this product on the preparative scale has not been described, but in view of the ratios of amounts and the separating problem outlined, cannot be economic. In addition, it is known that partially acylated di- or polyhydroxy compounds tend to acyl group migrations. When this occurs, for example, 35 in the course of the purification of the (R,S)-monooctanoate (for example in the chromatography on silica gel or in aqueous extraction) or in the course of a subsequent reaction (for example during the alkylation of the free hydroxyl group), this leads to a distinct reduction in the optical purity or to racemization.
3 The cis-configured (R,S)-diols and the diacylated (R,S)-compounds are not optically active and therefore not of interest. It is therefore an object of the present invention to develop a process which 5 does not have the disadvantages mentioned. The present invention provides a process for preparing a chiral, nonracemic compound of the formula I R1 '-10" R2 (I) 10 where: R 1 is R4 O R3 Ring A I N
(CH
2 )n R5 15 where: ring A is phenyl, 5-12 membered heteroaromatic ring which may contain 20 from one to four heteroatoms from the group of N, 0 and S, 8 to 14 membered aromatic ring, (C3-C8)-cycloalkyl; R 3 is H, F, Cl, Br, OH, NO 2 , CF 3 , OCF3, (C1-C6)-alkyl, (C 3
-C
8
)
cycloalkyl, phenyl; 25
R
4 , R 5 are H, F, Cl, Br, OH, NO 2 , CF3, OCF3, OCF2H, OCF2-CF3,
OCF
2 -CHF2, SCF 3 , 0-phenyl, (C1-C6)-alkyl, 0-(Cl-C6)-alkyl, 0
(C
1
-C
6 )-alkyl-O-(C1-C3)-alkyl; 30 n is from 1 to 3; 4 and R2 is (C1-C8)-alkyl where one or more CH 2 groups in the alkyl groups may be replaced by 0, CO, S, SO or SO2, and alkyl may be one to 5 trisubstituted by F, CI, Br, CF 3 , CN, NO 2 , NHAc, NHBoc, NH-CO C(CH3)3, hydroxyl, OCF 3 , 0-(C1-C6)-alkyl, COOH, CO-benzoxy, CO-O(C1-C6)-alkyl, tetrazole, thiazolidine-2,4-dione, indole and (C6-Clo)-aryl, where thiazolidine-2,4-dione and aryl may in turn be substituted by F, Cl, Br, CF 3 , CN, N02, NHAc, NHTs, NHBoc, 10 NHCbz, NH-CO-C(CH3)3, hydroxyl, OCF 3 , 0-(C1-C)-alkyl, COOH, CO-benzoxy, CO-O(C1-C6)-alkyl, (C1-C6)-alkyl, 0-(C1-C6)-alkyl or tetrazole, or; R2 is an OH protecting group (PG), for example benzyloxymethyl, 15 benzyl, para-methoxybenzyl or tert-butyldimethylsilyl; which comprises A) 2 20 a) alkylation (alk-R /alk-PG) reacting cis-1,3-cyclohexanediol of the formula (II) HO,, OH 25 with a compound of the formula (Ill) 1 2(I) X -R2 30 where R2 is as defined above and X 1 is Cl, Br, I, OMs (0-mesyl), OTs (O-tosyl), OTf (0-triflate); in the presence of bases in a suitable solvent to give a racemic compound 35 of the formula (IV) 5 H O ,, R 2 (IV) where R2 is as defined above; 5 b1) enzymatic ester formation (EF) + separation (S) subjecting the resulting compounds of the formula (IV) to stereoselective enzymatic ester formation (EF), in which the alcohols are admixed with an acyl donor, for example a vinyl ester R 6-0-CH=CH 2 or an acid anhydride 6 6 6 10 R -0- R , where R is as defined above, and the enzyme in an organic solvents, for example dichloromethane, and the resulting mixture is stirred at -20 to 800C and, after the reaction has ended, one stereoisomer is present as an ester of the formula (V) R6- , 0". R2 *0 ~ (V) 15 where R6 is C(=O)-(C1-C16)-alkyl, C(=O)-(C2-C16)-alkenyl, C(=O)-(C3-C16) alkynyl, C(=O)-(C3-C16)-cycloalkyl, where one or more carbon 20 atoms may be replaced by oxygen atoms and be substituted by 1-3 substituents from the group of F, Cl, Br, CF 3 , CN, N02, hydroxyl, methoxy, ethoxy, phenyl and CO-O(1-C4)-alkyl, CO-O(C2-C4) alkenyl, which may in turn be substituted by 1-3 substituents from the group of F, Cl, Br, CF3, and 25 R2 is as defined above, and the other stereoisomer is present unchanged as the alcohol of the formula (IV), and are therefore separated from each other by utilizing their 30 different chemical or physicochemical properties (for example Rf values or solubility differences in water or other solvents) (separation S), for example by simple chromatography on silica gel, by extraction (for example heptane/methanol or org. solvent/water) or else by a further subsequent 6 chemical reaction, for example of the alcohol, in which the ester does not take part, or 5 b2) enzymatic ester hydrolysis [=chemical esterification (CE) + enzymatic hydrolysis (EH)] + separation (S) subjecting the resulting compounds of the formula (IV) to a stereoselective 10 enzymatic ester hydrolysis, in which the racemic alcohol is initially converted by chemical esterification (CE), for example by means of acid 6_ 6_ 6 chlorides R -CI or acid anhydrides R -0- R , in the presence of bases, for example triethylamine, to the racemic ester of the formula (V)
NR
2 (v) 15 where R6 and R2 are each as defined above, which, to carry out the stereoselective enzymatic ester hydrolysis (EH), is 20 then taken up in homogeneous or heterogeneous, aqueous, aqueous organic or organic media, and reacted, in the presence of an enzyme in the case of hydrolysis with water and in the case of alcoholysis with an alcohol, for example n-butanol, at a temperature of 10-80*C, and after the reaction has ended, one stereoisomer is present as the alcohol of the formula (IV) 25 and the other is present unchanged as the ester of the formula (V) and can thus be separated from each other as described under b1), and the enantiomer of the formula (IV) occurring as an alcohol is further processed as described under d), or 30 c) chemical hydrolysis (CH) hydrolyzing the enantiomer of the formula (V) occurring as an ester to the chemically enantiomeric alcohol by known methods and 35 7 d) alkylation (alk- R 1 ) reacting further with a compound of the formula (VI) R4 R3 Ring A N
(CH
2 )n - X2 5 R5 where ring A, R 3 , R 4 , R 5 and n are each as defined above and 10 X2 is Cl, Br, I, OTs, OMs, OTf; in the presence of bases in a suitable solvent to give the compound of the formula (I), and 15 e) detachment of the protecting group PG (detPG) 22 if R is an OH protecting group (PG) as defined above and R 2 , converting the compound of the formula (la) 20 R 0 0 PG (la) where R and PG are each as defined above, 25 by detaching the protecting group by known methods, for example detachment of PG = benzyloxymethyl or PG = benzyl by hydrogenating over Pd/C, or detachment of PG = para-methoxybenzyl with, for example DDQ (2,3-dichloro-5,6-dicyanobenzoquinone), or detachment of PG = tert butyldimethylsilyl, for example with Bu 4 NF, 30 to a compound of the formula (VII) 8 R1 OH RI O (VII) where R is as defined above, 5 f) alkylation (alk- R 1 then reacting it with a compound of the formula (111) x1R 2 (11l) X1-R2 10 where X and R2 are each as defined above, in the presence of bases in a suitable solvent to give a compound of the formula (1), the product or the enantiomeric form, 15 it being also possible to change the sequence of individual reaction steps as described above under A): A) alk- R2 - EF + S/CE + EH + S [- CH] -alk- R [-DetPG -+ alk 20 R 2 ] -+ product/enantiomeric form to: B) alk- R -+ EF + S/CE + EH + S [-- CH] alk- R [ DetPG -alk 25 R 2 ] product/enantiomeric form or C) alk-PG - EF + S/CE + EH + S -CH -alk-R - DetPG -alk 30 R 1 -> product/enantiomeric form or 1 2 D) alk-PG -> EF + S/CE + EH + S -alk- R -* DetPG --* alk- R -4 35 product/enantiomeric form.
9 Possible process variants are illustrated hereinbelow in Schemes I to IV: o 0 C,0 00 0- 0 D- 0 -0 0- 40 0-a N 0 N 0 6cc I< 0 C0 + C) 0 (D 0 0 > 0 0 oo z (06 0 0 Ile 20 0 LU L) CUI
U,)
%0 o: E~C -0 E o- .2 0 0 <~ CY o ow 00 6 0 + < + L Lj 00 + 0 00 o 0 A co 1 00 L Co6 00 o 0: 0 i 00 (D~ %0~ 0 0 600 a_ la): 0~ C0 0 /L * 0 (N 0i 0 0 0 o 6 .0 x
I
CD 01 0 _ 0
CO,
CD I0 < 0 00E 6 0 0 < 0 00 0 00 00 0 0 CY) 0 0 / 0 03 0. 0 0 0 I6 (L) 2l 0 0 C." 1 0 60 00 00 CL o (D 0 00 0 0 0 + 6 0 (9 a 0 IL. 0 0 0 00 o 00 0D 0 0 C', Q. 0 Ir b 00 CDD aa 0 0 I II 0 (9 IL 0 0 w 2 0 Ci 16 The process according to the invention is economic, simple and rapid. The process completely eliminates the risk of acyl group migration, does not require equimolar amounts of optically pure starting materials or auxiliaries, any expensive reagents, any optical resolution by chromatography on chiral 5 phases, any disproportionately large amounts of solvent or any cost intensive working steps. The loss of 50% which is typical for optical resolutions can be avoided by using both enantiomers and changing the sequence of the alkylations. 10 Preference is given to what is known as the enantioconvergent method (see Scheme IV or Method C and D)) in which the procedure is, for example, as follows: alkylation of cis-1,3-cyclohexanediol of the formula (II) with a compound of the formula (111) with a PG selected as R2 such that PG can be detached again simply and selectively in the course of the further 15 synthesis, and PG is thus, for example, benzyl, or para-methoxybenzyl or tert-butyldimethylsilyl, subjecting the resulting compound of the formula (IV) to stereoselective enzymatic ester formation or ester hydrolysis (see above) and, after completion of separation of unconverted alcohol and ester, converting them separately and by different routes to the same 20 optically pure product by reacting the alcohol (as described in the first part), for example, with a compound of the formula (VI) to give a compound of the formula (Ia), then converting it by detaching the PG group to give a compound of the formula (VII), and then reacting it with a compound of the formula (111) where R2 is as desired in the product to give a compound of 25 the formula (1), and converting the isomeric ester by simple ester hydrolysis to a compound of the formula (IV), and then reacting with a compound of the formula (111) where R2 is as desired in the product to give a compound of the formula (Vill) R2 "PG (VIII) 30 then converting it by detaching the PG group to give a compound of the formula (IV) 17 O OH HO, V and then reacting it with a compound of the formula (VI) to give a compound of the formula (1). 5 O OR1 R1 ,,R2 R2 0RI R (I) Preference is given to using compounds of the formula (111) X1 - R 2 (Ill) 10 where X1 is Cl, Br, I, OMs or OTs, 15 particular preference to using those where X' is Cl, Br or 1. Preference is given to a process for preparing the compounds of the 20 formula (I) RI R2 I) where 25 R is 18 R4 R3 Ring A I tN
(CH
2 )n R5 where 5 ring A is phenyl, 5-12 membered heteroaromatic ring which may contain one or more heteroatoms from the group of N, 0 and S, fused/bicyclic 8 to 14 membered aromatic ring, (C3-C8)-cycloalkyl; R 3 is H, CF3, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, phenyl; 10
R
4 , R 5 are H, F, Br, CF 3 , OCF 3 , (Cl-C6)-alkyl, O-(C1-C6)-alkyl; n is from 1 to 2; 15 R2 is (C1-C8)-alkyl where one or more CH 2 groups in the alkyl groups may be replaced by 0, CO, S, SO or S02, and alkyl may be one to trisubstituted by F, Cl, Br, CF 3 , CN, N02, NHAc, NHBoc, NH-CO
C(CH
3
)
3 , hydroxyl, OCF 3 , O-(C1-C6)-alkyl, COOH, CO-benzoxy,
CO-O(C
1 -C6)-alkyl, tetrazole, thiazolidine-2,4-dione, indole and 20 (C6-C1o)-aryl, in which thiazolidine-2,4-dione and aryl may in turn be substituted by F, Cl, Br, CF 3 , CN, NO 2 , NHAc, NHTs, NHBoc, NHCbz, NH-CO-C(CH3)3, hydroxyl, OCF 3 , 0-(C1-C6)-alkyl, COOH, CO-benzoxy, CO-O(C 1 -C6)-alkyl, (C1-C6)-alkyl, 0-(C1-C6)-alkyl or tetrazole. 25 Particular preference is given to a process for preparing the compounds of the formula (1) 01* RI R2 (I) where: 30 R is 19 R4 R3 Ring A N
(CH
2 )n R5 where 5 ring A is phenyl; R 3 is (C1-C4)-alkyl;
R
4 , R 5 are H, (C1-C4)-alkyl, O-(C1-C4)-alkyl; 10 n is 1; R2 is (C1-C8)-alkyl where one or more CH2 groups in the alkyl groups may be replaced by 0, CO, S, SO or S02 and alkyl may be one to 15 trisubstituted by F, Cl, Br, CF 3 , CN, NO 2 , NHAc, NHBoc, NH-CO C(CH3)3, hydroxyl, OCF3, O-(C1-C6)-alkyl, COOH, CO-benzoxy, CO-O(Ci-C6)-alkyl, tetrazole, thiazolidine-2,4-dione, indole and (C6-C1o)-aryl, in where thiazolidine-2,4-dione and aryl may in turn be substituted by F, Cl, Br, CF3, CN, N02, NHAc, NHTs, NHBoc, 20 NHCbz, NH-CO-C(CH3)3, hydroxyl, OCF 3 , 0-(C1-C6)-alkyl, COOH, CO-benzoxy, CO-O(C1-C6)-alkyl, (C1-C6)-alkyl, 0-(C1-C6)-alkyl or tetrazole. 2 34 5 The alkyl radicals in the substituents R , R , R and R may be either 25 straight-chain or branched. In this context, a heteroaromatic ring refers to both mono- and bicyclic rings having a maximum of 4 heteroatoms, in particular those which contain up to 4 nitrogen atoms and/or 1 oxygen or 1 sulfur atom, for example furan, 30 thiophene, thiazole, oxazole, thiadiazole, triazole, pyridine, triazine, quinoline, isoquinoline, indole, benzothiophene, benzofuran, benzotriazole. Aromatic rings may be mono- or bicyclic and also be fused, for example naphthyl, benzo[1,3]dioxole, dihydrobenzo[1,4]dioxin.
20 The racemic, cis-configured 1,3-cyclohexane derivatives of the formula (IV) and of the formula (VII) are prepared by monoalkylating cis cyclohexanediol (compound of the formula 11), but can also be prepared by reductively opening appropriate acetals (R. Hunter et al., J. Org. Chem. 5 1993, 85, 6756), and also by reductive ether formation starting from silyl ethers and aldehydes or ketones (J.S. Bajwa, X. Jiang, J. Slade, K. Prasad, 0. Repic, T.J. Blacklock, Tetrahedron Lett. 2002, 43, 6709-6713). The alkylating reagents of the formula Ill are commercially obtainable or 10 can be prepared by literature methods, for example by free-radical side chain halogenation (see literature review by R.C. Larock, Comprehensive Organic Transformations, p. 313, 1989 VCH Publishers, Inc.) or from the alcohols or derivatives preparable therefrom (see literature review by R.C. Larock, Comprehensive Organic Transformations, p. 353-363, 1989 15 VCH Publishers, Inc.). Also known (see J. Chem. Soc. 1925, 127, 2275-2297; J. Chem. Soc. 1922, 121, 2202-2215) is the preparation of various 2-bromomethylbenzoyl bromides by free-radical bromination, which may then be converted by 20 further reaction with alcohols to the bromomethylbenzoic esters belonging to the group of the alkylating reagents of the formula 1ll. The alkylating reagents of the formula (VI) or the alcohols X2 = OH which can serve as precursors are commercially obtainable or can be prepared 25 by literature methods [a). The Chemistry of Heterocyclic Compounds (Ed.: A. Weissberger, E.C. Taylor): Oxazoles (Ed.: 1.J. Turchi); b) Methoden der Organischen Chemie, Houben-Weyl, 4 th edition, Hetarene 111, subvolume 1; c) 1. Simit, E. Chindris, Arch. Pharm. 1971, 304, 425; d) Y. Goto, M. Yamazaki, M. Hamana, Chem. Pharm. Bull. 1971, 19 (10), 2050-2057]. 30 The alkylating reagents of the formula Ill and VI are reacted with 1,3 cyclohexanediol or 1,3-cyclohexanediol derivatives in the presence of bases. Suitable bases are, for example, hydroxides such as KOH, carbonates such as CS2CO3, alkoxides such as KOtBu and also 35 compounds such as LDA, BuLi, LiHMDS, KH, NaH and NaHMDS. Suitable solvents are, for example, THF, MTBE, DME, NMP, DMF and chlorobenzene.
21 For optical resolution of the alcohols, they are taken up in organic solvents, for example dimethoxyethane (DME), methyl tert-butyl ether (MTBE), diisopropyl ether (DIPE), THF, n-hexane, cyclohexane, toluene, chlorobenzene, acetone, dimethylformamide (DMF), dichloromethane, 1,2 5 dichloroethane and tert-butanol, acyl donors such as vinyl acetate, vinyl propionate, vinyl butyrate, 2,2,2-trifluoroethyl 2H,2H-perfluorodecanoate, ethoxyvinyl acetate, p-nitro- or p-chlorophenyl acetate, oxime esters, acetic anhydride, propionic anhydride, succinic anhydride, glutaric anhydride, isovaleric anhydride, 2,2,2-trichloroethyl butyrate, 2,2,2-trifluoroethyl 10 2H,2H-perfluorodecanoate are added and the reaction mixture is subsequently admixed with a suitable enzyme and stirred at from -20 to 80 0 C. The proportion of cosolvent in the solution is preferably 10-90%, but it is in some cases also advantageous to carry out the enzymatic reaction in pure acyl donor, for example vinyl acetate, without cosolvent. 15 For optical resolution of the ester derivatives, for example acetyl-, propionyl-, butyryl- or glutaryl-, they are subjected in homogeneous or heterogeneous, aqueous, aqueous-organic or organic media, in the presence of a suitable enzyme, to stereoselective hydrolysis or alcoholysis 20 (for example with n-butanol) at a temperature of 10-80*C, optionally in the presence of cosolvents (see above) and of a buffer, the reaction mixture preferably containing 2-50% by weight of ester. The abovementioned ester derivatives can be prepared by literature 25 methods, for example by reacting the alcohol with acid chlorides such as acetyl chloride or anhydrides such as acetic anhydride, in the presence of an amine, for example triethylamine or pyridine (see literature review by R.C. Larock, Comprehensive Organic Transformations, p. 978, 1989 VCH Publishers, Inc.). 30 When the reaction has ended, the products or the enantiomers can be separated in a simple manner, for example by extraction by literature methods (a). T. Yamano, F. Kikumoto, S. Yamamoto, K. Miwa, M. Kawada, T. Ito, T. Ikemoto, K. Tomimatsu, Y. Mizuno, Chem. Lett. 2000, 448; 35 b). B. Hungerhoff, H. Sonnenschein, F. Theil, J. Org. Chem. 2002, 67, 1781] or by employing chromatographic methods. A further method is, on completion of the enzymatic reaction, to distinctly increase the water solubility of the remaining alcohol by derivatization, for example by acylation with cyclic anhydrides, e.g. with glutaric anhydride, or 22 by conversion to a cholin ester [a). H. Kunz, M. Buchholz, Chem. Ber. 1979, 112, 2145; b). M. Schelhaas, S. Glomsda, M. Hansler, H.-D. Jakubke, H. Waldmann, Angew. Chem. 1996, 108, 82] and thus to achieve separation from the water-insoluble or sparingly water-soluble 5 esters by extraction. After the separation, the derivatization of the alcohols can be reversed by chemical or enzymatic hydrolysis. A particularly interesting means for separating the enantiomers in the case of the enzymatic acylation is to select the acyl donor in such a way that the acylated enantiomer is distinctly more water-soluble than the unconverted 10 alcohol. Suitable acyl donors are, for example, cyclic anhydrides such as succinic anhydride. On completion of the enzymatic acylation, the acylation product bears a free carboxyl group which enables rapid removal of the product by aqueous extraction under basic conditions, for example with sat. aqueous NaHCO 3 solution. 15 In enzymatic optical resolution by ester hydrolysis, the procedure is preferably to admix an ester of the formula (I), for example where R= COCH 3 , COCH2CH3 or COCH 2
CH
2
CH
2 COOH in an aqueous or alcoholic solution, with an esterase or lipase and stirred. 20 It may be advantageous to buffer the solution mentioned, for example with phosphate or TRIS [= tris(hydroxymethyl)methylamine] buffer. The additive may, for example, be 0.01-1.0 molar. A favorable buffer range is pH 5-10. The enzymes used are preferably hydrolases from mammalian livers, for 25 example lipase from porcine pancreas (fluka), or from microorganisms, for example Lipase B from Candida antarctica (Roche Diagnostics), Lipase OF from Candida rugosa (Meito Sangyo), Lipase SL from Pseudomonas cepacia (Meito Sangyo), Lipase L-1 0 from Alcaligenes spec. (Roche Diagnostics), and Lipase QL from Alcaligenes spec. (Meito Sangyo). When 30 the esters used are glutaric acid derivatives, for example mono-(3 benzyloxycyclohexyl) glutarate, it may be advantageous, instead of the abovementioned lipases, to use glutaryl-7-ACA Acylase (Roche Diagnostics). Particular preference is given to using Lipase B from Candida antarctica 35 (Roche Diagnostics), and it may be advantageous to use the free enzyme or an immobilized form of the enzyme, for example one of the three products which are currently obtainable commercially.
23 Each of the enzymes mentioned can be used in free or in immobilized form (Immobilized Biocatalysts, W. Hartmeier, Springer Verlag Berlin, 1988). The amount of enzyme is selected freely depending on the reaction rate or on the desired reaction time and on the type of the enzyme (for example 5 free or immobilized) and can be determined easily by simple preliminary experiments. The enzyme can be recovered by freeze-drying. The removal (and optional later reuse) of the enzyme can be eased by immobilization. Suitable reaction control always succeeds in obtaining at least one 10 enantiomer in optically pure form. When optically pure ester is desired, the conversion in the case of an enzymatic ester formation should be less than (or equal to) 50%, or in the case of an enzymatic hydrolysis or alcoholysis, greater than (or equal to) 50%. When optically pure alcohol is desired, the conversion in the case of enzyme-catalyzed ester formation should be 15 greater than (or equal to) 50%, or in the case of hydrolysis or alcoholysis, less than (or equal to) 50%. The conversion of the enzymatic reaction was determined either by HPLC directly from the reaction mixture or by calculation from the optical purities of the reaction products (ester and acid) which were likewise determined 20 directly from the reaction mixture by HPLC on a chiral phase. The examples which follow are intended to illustrate the present invention in detail. 25 Examples: All isolated products and crude product mixtures were identified by 1H NMR and mass spectra or by HPLC. The optical purity of the esters and alcohols was determined by HPLC, for 30 example on Chiralpak AD 250 x 4.6 (Daicel) or Chiracel OD 250 x 4.6. Scheme la: Example 1 35 Synthesis of racemic methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate 24 HO,,, ,O rac. C0 2 Me 500 g (4.3 mol) of cis-1,3-cyclohexanediol were dissolved in 5 I of NMP and admixed with 336 g (3.0 mol) of potassium tert-butoxide (KOtBu). The 5 internal temperature rose to 280C. The mixture was stirred for 30 min, then cooled to -5*C and admixed dropwise with 370 g (approx. 94%, approx. 1.4 mol) of methyl 2-bromomethyl-6-methylbenzoate which may be prepared, for example, by methanolyzing 2-bromomethyl-6-methylbenzoyl bromide or by brominating methyl 2,6-dimethylbenzoate. The mixture was 10 stirred for 30 min and then diluted with 5 I of water. After washing three times with 3 I of n-heptane each time and discarding the n-heptane solutions, the remaining aqueous phase was extracted four times with 2.5 I of MTBE each time. The combined MTBE phases were washed once with 5 I of water, dried over Na 2
SO
4 and subsequently concentrated by 15 evaporation under reduced pressure. 234 g of the desired compound were obtained as a yellowish oil and were used in the next reaction (for example an optical resolution) without further purification; 1H NMR (CDCl3), 8 = 1.27 (m, 1H), 1.45 (m, 1H), 1.55 (m, 1H), 1.74 (m, 1H), 1.83 (m, 1H), 2.05 (m, 1H), 2.34 (s, 3H), 3.47 (m, 1H), 3.72 (m, 1H), 3.91 (s, 3H), 4.58 (dd, 2H), 20 7.15 (d, 1H), 7.20 (d, 2H), 7.27 (m, 1H). Example 2 Optical resolution of methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate 25 H0,,, 0 rac. CO 2 Me 490 g of the crude, racemic methyl cis-2-(3-hydroxycyclohexyloxymethyl) 6-methylbenzoate (see Example 1) were dissolved in 3.1 1 of methylene 30 chloride and 850 ml of vinyl acetate, admixed with 18 g of Novozym 435 and stirred at 21-24*C. After 28 h, a further 2 g of Novozym 435 were added. After a total of 44 h, the reaction was ended by filtering off the 25 enzyme and the filtrate was concentrated by evaporation under reduced pressure to obtain 540 g. Chromatography of the residue on approx. 6 kg of silica gel (1:1 ethyl acetate/n-heptane) gave 184 g of methyl (1R,3S)-2-(3 hydroxycyclohexyloxymethyl)-6-methylbenzoate; > 98% ee (HPLC on 5 Chiralpak AD-H 250 x 4.6; 1 ml/min, heptane/EtOH/CH3CN 25:1:0.5 + 0.1% TFA); H NMR (CDCl 3 ), 6 = 1.27 (m, 1H), 1.45 (m, 1H), 1.55 (m, 1H), 1.74 (m, 1H), 1.83 (m, 1H), 2.05 (m, 1H), 2.34 (s, 3H), 3.47 (m, 1H), 3.72 (m, 1H), 3.91 (s, 3H), 4.58 (dd, 2H), 7.15 (d, 1H), 7.20 (d, 2H), 7.27 (m, 1H) and 239 g of the (1S,3R)-acetate (93% ee, HPLC on Chiralcel OD/20 10 250 x 4.6, 1 ml/min, 100:1:0.5 heptane/EtOH/CH3CN). Example 3 Synthesis of 4-iodomethyl-2-(3-methoxyphenyl)-5-methyloxazole MeO 15 150.0 g (0.63 mol) of 4-chloromethyl-2-(3-methoxyphenyl)-5-methyloxazole were dissolved in 2.7 1 of THF and admixed with 106 g (0.71 mol) of Nal. The mixture was stirred for 4 h and left to stand overnight, the salts were 20 filtered off with suction and the filtrate was concentrated under reduced pressure. After approx. 1-2 hours, the desired iodide solidified, yield: 216 g, mp 58-59*C. H NMR (CDCl3): 6 = 2.30 (s, 3H), 3.88 (s, 3H), 4.34 (s, 2H), 6.97 (dd, 1H), 7.34 (t, 1H), 7.52 (d, 1H), 7.58 (d, 1H). 25 Example 4 Synthesis of methyl (1 R,3S)-2-{3-[2-(3-methoxyphenyl)-5-methyloxazol-4 ylmethoxy]cyclohexyl-1 -oxymethyl}-6-methylbenzoate MeO 0,. O
CO
2 M 30 184 g (0.66 mol) of methyl (1 R,3S)-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate (see Example 2) were dissolved in 2.2 I of t-BuOMe.
26 88.0 g (approx. 55%, 1.8 mmol) of NaH were added and the mixture was stirred at 20-22*C for 45 minutes. 282 g (83.8 mmol) of 4-iodomethyl-2-(3 methoxyphenyl)-5-methyloxazole (see Example 3) were added, and the mixture was stirred at 220C for 8 hours and left to stand overnight. The 5 mixture was stirred for a further 4 h and then, with cooling, 200 ml of water were added cautiously, and later a further 1.5 1. The organic phase was removed, dried (Na2SO 4 ) and concentrated under reduced pressure. 383 g of crude product were obtained and were chromatographed on approx. 6 kg of silica gel (19:1 dichloromethane/acetone), yield: 199 g of a 10 yellowish oil; 1H NMR (CDCl 3 ), 8 = 1.15-1.32 (m, 4H), 1.81 (m, 1H), 2.00 (m, 1H), 2.07 (m, 1H), 2.34 (s, 3H), 2.40 (s, 3H), 2.51 (m, 1H), 3.27 (m, 1H), 3.37 (m, 1H), 3.87 (s, 3H), 3.90 (m, 3H), 4.48 (s, 2H), 4.60 (s, 2H), 6.96 (m, 1H), 7.12-7.35 (m, 4H), 7.53 (s, 1H), 7.58 (d, 1H). 15 Example 5 Synthesis of (1 R,3S)-2-{3-[2-(3-methoxyphenyl)-5-methyloxazol-4 ylmethoxy]cyclohexyl-1-oxymethyl}-6-methylbenzoic acid MeO O N C0 2 H 20 199 g (0.41 mol) of methyl (1 R,3S)-2-{3-[2-(3-methoxyphenyl)-5 methyloxazol-4-ylimethoxy]cyclohexyl- 1 -oxymethyl}-6-methylbenzoate (see Example 4) were dissolved in 2 I of ethanol. 250 ml of 33% NaOH were added and the mixture was heated to reflux for 15 hours. Ethanol was 25 distilled off under reduced pressure, and the residue was dissolved in approx. 2 I of water and washed four times with 500 ml of MTB ether each time. The aqueous phase was acidified to pH 1 using conc. hydrochloric acid with cooling, and the oily product was extracted using 1.5 I of ethyl acetate. The ethyl acetate solution was dried and concentrated under 30 reduced pressure. The residue was dissolved in 1.2 I of DIPE at approx. 400C. Crystallization and drying under reduced pressure at 600C resulted in 132.5 g of the desired carboxylic acid; mp 103-105*C; > 98% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 90:7:1 heptane/EtOH/CH3CN + 0.1% TFA); H NMR (CDCI3), 6 = 1.14-1.38 (m, 4H), 1.80 (m, 1H), 1.93 (m, 2H), 35 2.41 (s, 3H), 2.44 (s, 3H), 2.61 (m, 1H), 3.40 (m, 2H), 3.86 (s, 3H), 4.53 (s, 27 2H), 4.68 (dd, 2H), 6.98 (dd, 1H), 7.17-7.36 (m, 4H), 7.55 (s, 1H), 7.61 (d, 1H). Example 6 5 Synthesis of 4-iodomethyl-2-(4-methylphenyl)-5-methyloxazole - -4N D I 6.0 g of 4-chloromethyl-2-(4-methylphenyl)-5-methyloxazole were dissolved 10 in 120 ml of THF and admixed with 4.18 g (27.9 mmol) of Nal. The mixture was stirred for 3.5 h, a further 1.5 g of Nal were added and the mixture was heated to 350C. After 30 minutes, the salts were filtered off with suction and the filtrate was concentrated under reduced pressure; yield: 10.1 g, mp 104-1050C; 1H NMR (CDC3): 8 = 2.29 (s, 3H), 2.39 (s, 3H), 4.34 (s, 15 2H), 7.24 (d, 2H), 7.88 (d, 2H). Example 7 Synthesis of methyl (1 R,3S)-2-{3-[2-(4-methylphenyl)-5-methyloxazol-4 ylmethoxy]cyclohexyl-1 -oxymethyl}-6-methylbenzoate 20 'o . , o Nco 36.0 g (0.129 mol) of methyl (1 R,3S)-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate (see Example 2) were dissolved in 430 ml of tBuOMe. 25 17.2 g (approx. 55%, 0.35 mol) of NaH were added and the mixture was stirred at 230C for 30 minutes. 55.1 g (0.166 mol) of 4-iodomethyl-2-(4 methylphenyl)-5-methyloxazole (Example 6) were added. After stirring for 6 hours and leaving to stand over 2 days, 400 ml of water were added and the organic phase was removed. After drying (Na2SO4) and concentrating, 30 the crude product (75 g) was chromatographed on silica gel (approx. 1 kg) (19:1 dichloromethane/acetone), yield: 42 g of the dialkylated 1,3 cyclohexanediol derivative as a yellowish oil; H NMR (CDCl 3 ), 8 = 1.16 1.31 (m, 4H), 1.80 (m, 1H), 1.97-2.1 (m, 2H), 2.34 (s, 3H), 2.39 (s, 3H), 28 2.40 (s, 3H), 2.52 (m, 1H), 3.27 (m, 1H), 3.37 (m, 1H), 3.89 (s, 3H), 4.47 (s, 2H), 4.59 (s, 2H), 7.13 (d, 1H), 7.20-7.28 (m, 4H), 7.88 (d, 1H). Example 8 5 Synthesis of (1 R, 3S)-2-{3-[2-(4-methylphenyl)-5-methyloxazol-4-yl methoxy]cyclohexyl- 1 -oxymethyl}-6-methylbenzoic acid C0 2 H 10 42.0 g (0.09 mol) of methyl (1 R,3S)-2-{3-[2-(4-methylphenyl)-5 methyloxazol-4-ylmethoxy]cyclohexyl-1-oxymethyl}-6-methylbenzoate (see Example 7) were dissolved in 420 ml of ethanol. 45 ml of 33% NaOH were added and the mixture was heated to reflux for approx. 20 hours. Ethanol was distilled off under reduced pressure, the residue was dissolved in 15 500 ml of water and the solution was washed four times with in each case 100 ml of MTB ether. The aqueous phase was acidified (pH 1) using conc. hydrochloric acid with cooling and the oily product was extracted using ethyl acetate. The ethyl acetate solution was dried and concentrated under reduced pressure. The residue was dissolved in 250 ml of DIPE with 20 heating. On cooling, the crystallization set in. When the crystallization had ended, and after drying under reduced pressure at 60*C, 28.4 g of the desired carboxylic acid were obtained; mp 117-119C; > 98% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 90:7:1 heptane/EtOH/CH 3 CN + 0.1% TFA); H NMR (CDCl 3 ), 5 = 1.14-1.36 (m, 4H), 1.80 (m, 1H), 1.91 (m, 2H), 25 2.39 (s, 3H), 2.40 (s, 3H), 2.46 (s, 3H), 2.64 (m, 1H), 3.40 (m, 2H), 4.54 (s, 2H), 4.68 (dd, 2H), 7.17-7.30 (m, 5H), 7.91 (d, 2H). Example 9 Synthesis of 4-iodomethyl-2-(3-methylphenyl)-5-methyloxazole 30 / \ - xN 29 6.0 g of 4-chloromethyl-2-(4-methylphenyl)-5-methyloxazole were dissolved in 120 ml THF and admixed with 4.5 g (30 mmol) of Nal. The mixture was stirred for 5 h and then left to stand overnight. The removal of the solid and concentration of the filtrate under reduced pressure gave 10.2 g of the 5 desired iodide; mp - 32*C; H NMR (CDCl3): 8 = 2.30 (s, 3H), 2.40 (s, 3H), 4.34 (s, 2H), 7.24 (d, 1H), 7.32 (t, 1H), 7.77 (d, 1H), 7.83 (d, 1H). Example 10 Synthesis of methyl (1 R,3S)-2-{3-[2-(3-methylphenyl)-5-methyloxazol-4 10 ylmethoxy]cyclohexyl-1 -oxymethyl}-6-methylbenzoate N 14- 0 2 1Me 36.0 g (0.129 mol) of methyl (1R,3S)-2-(3-hydroxycyclohexyloxymethyl)-6 15 methylbenzoate (see Example 2) were dissolved in 430 ml of tBuOMe. 17.19 g (approx. 55%, 0.35 mol) of NaH were added and the mixture was stirred at 20-22*C for 30 minutes. 55.1 g (0.166 mol) of 4-iodomethyl-2-(3 methylphenyl)-5-methyloxazole (see Example 9) were added. After stirring for 6 hours and leaving to stand over 2 days, 400 ml of water were added 20 with cooling and the organic phase was removed. After drying (Na2SO4) and concentrating, the crude product (75 g) was chromatographed on silica gel (1.2 kg) (19:1 dichloromethane/acetone), yield: 49 g of methyl (1R,3S) 2-{3-[2-(3-methylphenyl)-5-meth loxazol-4-ylmethoxy]cyclohexyl-1 oxymethyl}-6-methylbenzoate; H NMR (CDCl 3 ), 8 = 1.13-1.31 (m, 4H), 25 1.80 (m, 1H), 1.97-2.1 (m, 2H), 2.34 (s, 3H), 2.40 (s, 3H), 2.41 (s, 3H), 2.52 (m, 1H), 3.27 (m, 1H), 3.37 (m, 1H), 3.90 (s, 3H), 4.48 (s, 2H), 4.59 (s, 2H), 7.12-7.33 (m, 4H), 7.78 (d, 1H), 7.84 (s, 1H). Example 11 30 Synthesis of (1 R,3S)-2-{3-[2-(3-methylphenyl)-5-methyloxazol-4 ylmethoxy]cyclohexyl-1 -oxymethyl}-6-methylbenzoic acid 30 N00 ,.. O C0 2 H 49.0 g (0.09 mol) of methyl (1R,3S)-2-{3-[2-(3-methylphenyl)-5 methyloxazol-4-ylmethoxy]cyclohexyl-1-oxymethyl}-6-methylbenzoate (see 5 Example 10) were dissolved in 500 ml of ethanol. 50 ml of 33% NaOH were added and the mixture was heated to reflux for approx. 14 hours. Ethanol was dissolved off under reduced pressure, the residue was dissolved in 500 ml of water and the solution was washed three times with in each case 150 ml of MTB ether. The aqueous phase was acidified (pH 1) using conc. 10 hydrochloric acid with cooling, and the oily product was extracted with ethyl acetate. The ethyl acetate solution was dried and concentrated under reduced pressure. The residue was dissolved in 250 ml of DIPE with heating. On cooling, crystallization set in. When the crystallization has ended, and after drying under reduced pressure at 60 0 C, 29.9 g of the 15 desired carboxylic acid are obtained; mp 109-111*C; > 98% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 90:7:1 heptane/EtOH/CH3CN +0.1% TFA); H NMR (CDC3), 5 = 1.14-1.36 (m, 4H), 1.80 (m, 1H), 1.93 (m, 2H), 2.40 (s, 2 x 3H), 2.45 (s, 3H), 2.64 (m, 1 H), 3.40 (m, 2H), 4.53 (s, 2H), 4.68 (dd, 2H), 7.17-7.34 (m, 5H), 7.81 (d, 1H), 7.85 (s, 1H). 20 Scheme Ila Example 12 Optical resolution of cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4 25 ylmethoxy]cyclohexan-1 -ol MeO O OH rac. 24.9 g of the racemic cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4 30 ylmethoxy]cyclohexan-1-ol (prepared by alkylating cis-1,3-cyclohexanediol with 4-iodomethyl-2-(3-methoxyphenyl)-5-methyloxazole) were dissolved in 100 ml of vinyl acetate, admixed with 1.0 g of Chirazyme L-2, lyo., and 31 stirred at 20-23 0 C. After about 30 minutes, the enzyme was filtered off and the solution concentrated under reduced pressure, crude product: 25.8 g. After chromatography on silica gel (10:1-0:1 n-heptane/ethyl acetate), 13.7 g of (1 S,3R)-3-[2-(3-methoxyphenyl)-5-methyloxazol-4 5 ylmethoxy]cyclohexan-1-ol and 11.3 g of the (1R,3S)-acetyl compound were obtained. Example 13 Preparation of (1 R,3S)-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-yl 10 methoxylcyclohexan-1 -ol 0 MeO 0, OH N 11.2 g of the (1R,3S)-acetate from Example 12 were dissolved in approx. 15 100 ml of MeOH, admixed with 0.5 ml of NaOMe (30%) and stirred at 20-23*C. After 3.5 h, the mixture was neutralized with concentrated acetic acid, taken up with ethyl acetate, washed with NaHCO 3 , dried over Na2SO4 and concentrated under reduced pressure. After filtration through silica gel (10:1-0:1 n-heptane/ethyl acetate), 8.8 g of (1R,3S)-3-[2-(3 20 methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexan-1-ol having 92% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 90:7:1 heptane/EtOH/CH3CN + 0.1% TFA) were obtained. Example 14 25 Synthesis of methyl (1R,3S)-2-{3-[2-(3-methoxyphenyl)-5-methyloxazol-4 ylmethoxy]cyclohexyl-1 -oxymethyl}-6-methylbenzoate 0 MeO ~- N K>f CO 2 M 30 1.4 g (4.4 mmol) of (1R,3S)-3-[2-(3-methoxyphenyl)-5-methyloxazol-4 ylmethoxy]cyclohexanol (see Example 13) were taken up in 15 ml of tBuOMe, admixed at 24-27*C with 1.20 g (10.7 mmol) of KOtBu and stirred 32 for approx. 30 minutes. The mixture was cooled to 0-5*C, 1.89 g (approx. 94%, approx. 7.4 mmol) of methyl 2-bromomethyl-6-methylbenzoate were added dropwise and the mixture was stirred at 0-50C for an initial 30 minutes. Without further cooling, the reaction mixture had a temperature of 5 approx. 200C after 1.5 hours. After stirring overnight and adding approx. 200 mg of KOtBu, the reaction was complete after stirring at 22*C for a further hour. Distilling off the solvent under reduced pressure, partitioning the residue between water and tBuOMe and drying the product-containing organic phase resulted, after concentrating under reduced pressure, in 10 1.6 g of methyl (1R,3S)-2-{3-[2-(3-methoxyphenyl)-5-methyloxazol-4 ylmethoxy]cyclohexyl-1-oxymethyl}-6-methylbenzoate as a yellowish oil; H NMR (CDCl 3 ), 8 = 1.15-1.32 (m, 4H), 1.81 (m, 1H), 2.00 (m, 1H), 2.07 (m, 1H), 2.34 (s, 3H), 2.40 (s, 3H), 2.51 (m, 1H), 3.27 (m, 1H), 3.37 (m, 1H), 3.87 (s, 3H), 3.90 (s, 3H), 4.48 (s, 2H), 4.60 (s, 2H), 6.96 (m, 1H), 15 7.12-7.35 (m, 4H), 7.53-7.60 (m, 2H). Example 15 Synthesis of methyl (1S,3R)-2-{3-[2-(3-methoxyphenyl)-5-methyloxazol-4 ylmethoxy]cyclohexyl-1 -oxymethyl}-6-methylbenzoate 20 MeO O O Starting from (1 S,3R)-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-yl methoxy]cyclohexan-1-ol from Example 12, alkylation in a similar manner to Example 14 gives (1S,3R)-2-{3-[2-(3-methoxyphenyl)-5-methyloxazol-4 25 ylmethoxy]cyclohexyl-1-oxymethyl}-6-methylbenzoate; the H NMR data agree with those in Example 14. Example 16 Optical resolution of cis-3-[2-(4-fluorophenyl)oxazol-4-ylmethoxy] 30 cyclohexan-1-ol, preparation of (1S,3R)-3-[2-(4-fluorophenyl)oxazol-4 ylmethoxy]cyclohexan-1 -ol 33 0 F N 30 mg of racemic cis-3-[2-(4-fluorophenyl)oxazol-4-ylmethoxy]cyclohexan 1-ol were taken up in about 3 ml dichloromethane, admixed with 60 mg of 5 p-nitrophenyl acetate and stirred at 20-23 0 C with 10 mg of Novozyme 435. After 70 h, the immobilized enzyme was filtered off. The determination of the optical purity directly from the reaction mixture which had been concentrated by evaporation gave > 95% ee (HPLC on Chiralpak AD 250 x 4.6; 1 ml/min, acetonitrile) for (1 S,3R)-3-[2-(4-fluorophenyl)oxazol-4 10 ylmethoxy]cyclohexan-1-ol and 95% ee for the (1R,3S)-acetate (HPLC on Chiralpak AD 250 x 4.6; 1 ml/min, acetonitrile). To isolate (1S,3R)-3-[2-(4 fluorophenyl)oxazol-4-ylmethoxy]cyclohexan-1-ol, the crude mixture was chromatographed on silica gel (ethyl acetate/n-heptane); yield 12 mg, 96% ee. 15 Example 17 Synthesis of methyl (1S,3R)-2-{3-[2-(4-fluorophenyl)oxazol-4-ylmethoxy] cyclohexyl-1 -oxymethyl}-6-methylbenzoate 0 0 N ",a aCO 2 Me 20 F Starting from (1S,3R)-3-[2-(4-fluorophenyl)oxazol-4-ylmethoxy]cyclohexan 1-ol from Example 16, alkylation with methyl 2-bromomethyl-6 methylbenzoate gives methyl (iS,3R)-2-{3-[2-(4-fluorophenyl)oxazol-4-yl 25 methoxy]cyclohexyl-1-oxymethyl}-6-methylbenzoate (see Example 35). Example 18 Optical resolution of 3-[2-(4-methylphenyl)-5-methyloxazol-4-yl methoxy]cyclohexan-1 -ol 30 34 'N O, ~ OH N rac. where R4 = p-Me-, R = H and R3 = Me) 5 16.3 g of the racemic 3-[2-(4-methylphenyl)-5-methyloxazol-4-yl methoxy]cyclohexan-1-ol were dissolved in 100 ml of vinyl acetate, admixed with 1.9 g of Chirazyme L-2, lyo., and stirred at 20-23*C. After about 30 minutes, the enzyme was filtered off and the solution concentrated under reduced pressure, crude product: 16.6 g. After 10 chromatography on silica gel (10:1-0:1 n-heptane/ethyl acetate), 8.6 g of (1 S,3R)-3-[2-(4-methylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexan-1 -ol and 6.8 g of the (1R,3S)-acetate are obtained. Example 19 15 Preparation of (1R,3S)-3-[2-(4-methylphenyl)-5-methyloxazol-4-ylmethoxy] cyclohexan-1-ol 20 6.8 g of the (1 R,3S)-acetyl compound from the Example 18 were dissolved in approx. 65 ml of MeOH, admixed with 0.32 ml of NaOMe (30%) and stirred at 20-23 0 C. After 4 h, the mixture was neutralized with acetic acid, concentrated under reduced pressure, taken up with ethyl acetate, washed with NaHCO3, dried (Na2SO4) and concentrated under reduced pressure. 25 After filtration through silica gel (10:1-0:1 n-heptane/ethyl acetate), 8.8 g of the desired (1 R,3S)-3-[2-(4-methylphenyl)-5-methyloxazol-4-ylmethoxy] cyclohexan-1-ol with 95% ee (HPLC on Chiralpak AD 250 x 4.6; 1 ml/min, 90:7:1 heptane/EtOH/CH3CN + 0.1% TFA) are obtained. 30 Example 20 Optical resolution of cis-3-[2-phenyl-5-methyloxazol-4-ylmethoxy] cyclohexan-1-ol 35 00~0 O OH N rac. 2.0 g of racemic cis-3-[2-phenyl-5-methyloxazol-4-ylmethoxy]cyclohexan-1 5 ol were dissolved in 50 ml of vinyl acetate, admixed with 0.1 g of Chirazyme L-2, lyo., and stirred at 20-23*C. After about 5 h, the enzyme was filtered off and the solution concentrated under reduced pressure. After chromatography on silica gel (2:1-1:2 n-heptane/ethyl acetate), 1.0 g of (1S,3R)-3-[2-phenyl-5-methyloxazol-4-ylmethoxy]cyclohexan-1-ol was 10 obtained as a bright yellow solid and 0.96 g of the acetylated (1R,3S) compound as a colorless oil. Example 21 Preparation of (1 R,3S)-3-[2-phenyl-5-methyloxazol-4-ylmethoxy] 15 cyclohexan-1-ol o 0, , OH N 0.96 g of the (1R,3S)-acetyl compound from Example 20 was dissolved in 20 approx. 5-10 ml of MeOH, admixed with 0.1 ml of NaOMe (30%) and stirred at 20-23"C. After 3 h, the mixture was neutralized with acetic acid and concentrated under reduced pressure, taken up with ethyl acetate, washed with saturated NaHCO3, dried (MgSO4) and concentrated under reduced pressure. After filtration through silica gel (10:1-0:1 n-heptane/ethyl 25 acetate), 0.84 g of the desired (1R,3S)-3-[2-phenyl-5-methyloxazol-4 ylmethoxy]cyclohexan-1-ol having 95% ee (HPLC on Chiralpak AD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA) was obtained. 30 Example 22 Optical resolution of cis-3-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl methoxy]cyclohexan-1 -ol 36 0e O,, OH N MeQ& rac 2.0 g of the racemic cis-3-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl 5 methoxy]cyclohexan-1-ol were dissolved in 50 ml of vinyl acetate, admixed with 0.1 g of Chirazyme L-2, lyo., and stirred at 20-23 0 C. After about 5 h, the enzyme was filtered off and the solution concentrated under reduced pressure. After chromatography on silica gel (2:1-1:2 n-heptane/ethyl acetate), 1.16 g of (1S, 3R)-3-[2-(4-methoxyphenyl)-5-methyloxazol-4 10 ylmethoxy]cyclohexan-1-ol and 0.79 g of the (1R,3S)-acetate were obtained. Example 23 Preparation of (1 R,3S)-3-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl 15 methoxy]cyclohexan-1 -ol N0~0 MeOO 0.79 g of acetate from Example 22 were dissolved in approx. 5-10 ml of 20 MeOH, admixed with 0.1 ml of NaOMe (30%) and stirred at 20-23 0 C. After 3 h, the mixture was neutralized with dilute acetic acid and concentrated under reduced pressure, taken up with ethyl acetate, washed with saturated NaHCO3, dried (MgSO4) and concentrated under reduced pressure. After filtration through silica gel (10:1-0:1 n-heptane/ethyl 25 acetate), 0.84 g of (1R,3S)-3-[2-(4-methoxyphenyl)-5-methyloxazol-4 ylmethoxy]cyclohexan-1-ol were obtained as a yellow oil having 92% ee (HPLC on Chiralpak AD 250 x 4.6; 1 ml/min, 90:7:1 heptane/EtOH/CH 3 CN + 0.1% TFA).
37 Example 24 Optical resolution of cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-yl methoxy]cyclohexan-1 -ol 0 N ~ 0 5 FO, rac. 1.70 g of the racemic cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-yl methoxy]cyclohexan-1-ol were dissolved in 50 ml of vinyl acetate, admixed with 0.1 g of Chirazyme L-2, lyo., and stirred at 20-23*C. After about 1.5 h, 10 the enzyme was filtered off and the solution concentrated under reduced pressure. After chromatography on silica gel (5:1-1:1 n-heptane/ethyl acetate), 1.0 g of (1 S,3R)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-yl methoxy]cyclohexan-1-ol and 0.75 g of the (1R,3S)-acetate were obtained. 15 Example 25 Preparation of (1R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy] cyclohexan-1-ol N F& 20 0.75 g of acetate from Example 24 was dissolved in approx. 30 ml of MeOH, admixed with 0.2 ml of NaOMe (30%) and stirred at 20-23*C. After 1 h, the mixture was neutralized with dilute acetic acid and concentrated under reduced pressure, taken up with ethyl acetate, washed with 25 saturated NaHCO3, dried (MgSO4) and concentrated under reduced pressure, yield: 0.59 g of (1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4 ylmethoxy]cyclohexan-1-ol as a white solid having 94% ee (HPLC on Chiralpak OD/19 250 x 4.6; 1 ml/min, 110:2:1 heptane/EtOH/CH 3 CN + 0.05% TFA).
38 Scheme lib Example 26 Stereoselective hydrolysis of 3-[2-(4-fluorophenyl)oxazol-4-ylmethoxyl] 5 cyclohexyl acetate, preparation of (1R,3S)-3-[2-(4-fluorophenyl)oxazol-4-yl methoxy]cyclohexan-1 -ol F O OH N 10 Approx. 10 mg of 3-[2-(4-fluorophenyl)oxazol-4-ylmethoxyl]cyclohexy acetate (prepared by reacting 3-benzyloxycyclohexan-1-ol with acetic anhydride, in a similar manner to the synthesis of mono(3 benzyloxycyclohexyl) glutarate see Example 39) were taken up in 2 ml of phosphate buffer (0.1 M, pH = 7.0) and 2 ml of DME and stirred with 15 approx. 5 mg of Chirazyme L-2, lyo., at 20-23*C for approx. 20-24 h. The reaction mixture was extracted with dichloromethane. The organic phase was admixed with toluene and concentrated by evaporation under reduced pressure. The determination of the optical purity for (1R,3S)-3-[2-(4 fluorophenyl)oxazol-4-ylmethoxy]cyclohexan-1-ol gave 99.4% ee (HPLC on 20 Chiralpak AD 250 x 4.6; 1 ml/min, acetonitrile) and 98.9% ee for the (1S,3R)-acetate (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 110:5:1 heptane/EtOH/CH3CN + 0.1% TFA). Scheme Ilila 25 Example 27 Synthesis of racemic cis-3-benzyloxycyclohexan-1 -ol HO,, .O. rac. 30 150.0 g (1.29 mol) of cis-1,3-cyclohexanediol were dissolved in 1.5 1 of NMP, admixed with 111.6 g (0.99 mol) of potassium tert-butoxide (KOtBu) 39 and stirred at 25-27*C. After about 30 minutes, the mixture was cooled to 00C and admixed dropwise with 78.1 g (0.46 mol) of benzyl bromide. The mixture was stirred at approx. 0*C for 15 min and then 1.5 I of water were added. After washing three times with 700 ml of n-heptane and discarding 5 the n-heptane solutions, the aqueous solution was extracted four times with 500 ml of MTBE. The combined MTBE phases were washed twice with in each case 1 1 of water, dried (Na2SO 4 ) and subsequently concentrated by evaporation under reduced pressure. 48.0 g of the desired compound were obtained as a clear, yellow oil; H NMR (CDCl3), 6 = 1.29 (m, 1H), 10 1.43-1.93 (m, 6H), 2.06 (m, 1H), 2.55 (s (br.), 1H), 3.56 (m, 1H), 3.74 (br, 1H), 4.55 (dd, 2H), 7.25-7.36 (m, 5H). Example 28 Optical resolution of 3-benzyloxycyclohexan-1-ol 15 HO,,. ,,0 rac. 20.3 g of cis-3-benzyloxycyclohexan-1-ol were dissolved in 35 ml of vinyl acetate and 125 ml of methylene chloride, admixed with 2.0 g of Novozym 20 435 and stirred at 20-23*C for 6 h. After leaving to stand overnight, the enzyme was filtered off. A sample was withdrawn and concentrated by evaporation under reduced pressure. The enantiomeric excess of (1S,3R) 3-benzyloxycyclohexan-1-ol was > 99% (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA), and the 25 enantiomeric excess of the (1R,3S)-acetate was 78% (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 100:1:0.5 heptane/EtOH/CH3CN). Example 29 Optical resolution of 3-benzyloxycyclohexan-1-ol 30 H O,,. ,O rac.
40 100.0 g of cis-3-benzyloxycyclohexan-1-ol were dissolved in 170 ml of vinyl acetate and 630 ml of methylene chloride, admixed with 5.0 g of Novozym 435 and stirred at 20-23*C for 26 h. The enzyme was filtered off, and a 5 sample was withdrawn and concentrated by evaporation under reduced pressure. The enantiomeric excess of (1S,3R)-3-benzyloxycyclohexan-1-ol was > 99% (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA), and the enantiomeric excess of the (1 R,3S)-acetate was 90% (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 10 100:1:0.5 heptane/EtOH/CH3CN). Example 30 Isolation of (1S,3R)-3-benzyloxycyclohexan-1-ol, separation of the mixture of acetate and alcohol with pyridine-S0 3 15 1.9 g of the crude acetate/alcohol mixture from the stereoselective enzymatic acetylation of 3-benzyloxycyclohexan-1-ol (from Example 29) were stirred with 2 g of pyridine-S03 at 20-22 0 C in 10 ml of pyridine and 2 ml of DMF. After 4 h, the conversion of the benzylcyclohexanol to the 20 pyridine salt of the sulfuric ester was virtually quantitative. The reaction mixture was diluted with 40 ml of water and extracted twice with approx. 20 ml of MTBE. The MTBE phases contain the unchanged (1 R,3S)-acetate quantitatively. The remaining, acetate-free aqueous phase was concentrated by evaporation under reduced pressure. The residue was 25 admixed with MTBE, and the sulfation product solidified; yield: 2.7 g. 2.7 g of pyridine salt of the sulfuric ester of (1S,3R)-benzylcyclohexan-1-ol were stirred at 55 0 C in 45 ml of THF, 4 ml of water and 1 ml of conc. sulfuric acid for 2 h. The mixture was admixed with 40 ml of water, approx. 30 10 ml of MTBE were added, the phases were separated and the aqueous phase was extracted once with MTBE. The combined organic phases were dried (Na2SO4) and concentrated by evaporation; yield: 640 mg of a bright yellow oil. The NMR data agree with the data quoted in Example 16; the testing of the optical purity gave > 99% ee. 35 Example 31 Isolation of (1S,3R)-3-benzyloxycyclohexan-1-ol, separation of the mixture of acetate and alcohol by extraction 41 10 g of the crude acetate/alcohol mixture from Example 29 were taken up in approx. 90 ml of methanol and approx. 70 ml of water and washed three times with in each case approx. 50 ml of n-heptane. The combined heptane phases (contain predominantly the acetate) are extracted with 50 ml of 1:1 5 methanol/water. The combined aqueous phases are washed again with n-heptane. After concentrating the aqueous phase, 3.6 g of the desired (1S,3R)-3-benzyloxycyclohexan-1-ol were obtained, and the concentration of the combined heptane phases gave 5.5 g of the (1 R,3S)-acetate. 10 Example 32 Synthesis of 4-iodomethyl-2-(4-fluorophenyl)oxazole F < -0 N 15 4.0 g (18.9 mmol) of 4-chloromethyl-2-(4-fluorophenyl)oxazole were dissolved in 80 ml of THF and admixed with 3.18 g (21.2 mmol) of Nal. The mixture was stirred at 20-23*C for 3 h and at 50 0 C for about 12 h, the salts were filtered off with suction and the filtrate was concentrated under reduced pressure, yield: 6.1 g. The product crystallized; mp 100-102*C; 20 H NMR (CDCl3): 8 = 4.34 (s, 2H), 6.97 (dd, 1H), 7.14 (m, 2H), 7.68 (s, 1H), 8.03 (m, 2H). Example 33 Synthesis of (1S,3R)-4-(3-benzyloxycyclohexyl-1 -oxymethyl)-2-(4 25 fluorophenyl)oxazole N 2.0 g (9.7 mmol) of (1S,3R)-3-benzyloxycyclohexan-1-ol were dissolved in 30 35 ml of tBuOMe. 1.3 g (approx. 55%, 43.7 mmol) of NaH were added and the mixture was stirred at 22"C for 60 minutes. 3.9 g (12.9 mmol) of 4 iodomethyl-2-(4-fluorophenyl)oxazole (Example 32) were added and the mixture was stirred at 22-23 0 C for about 3 hours. After leaving to stand 42 overnight, the mixture was stirred at 22-23*C for a further 11 h. Water (approx. 30 ml) was added with cooling and the organic phase was removed. Drying (Na2SO4), concentrating (crude yield: 4.5 g) and chromatography on silica gel (19:1 dichloromethane/acetone) gave 2.4 g of 5 the desired, cis-configured, optically pure, dialkylated 1,3-cyclohexanediol derivative as a white solid; mp 61-62*C; H NMR (CDCl3), 6 = 1.11-1.39 (m, 4H), 1.82 (m, 1H), 2.07 (m, 2H), 2.55 (m, 1H), 3.38 (m, 2H), 4.55 (s, 2H), 4.57 (s, 2H), 7.13 (m, 2H), 7.25-7.35 (m, 5H), 7.63 (s, 1H), 8.02 (m, 2H). 10 Example 34 Synthesis of (1R,3S)-3-[2-(4-fluorophenyl)oxazol-4-ylmethoxy]cyclohexano by hydrogenation 0 15 2.4 g of (1S,3R)-4-(3-benzyloxycyclohexyl-1 -oxymethyl)-2-(4-fluorophenyl) oxazole were dissolved in approx. 40 ml of methanol, admixed with a spatula tip of Pd/C (10%, comprising 50% water) hydrogenated at 20-23*C 20 under atmospheric pressure for approx. 8 hours. Filtering off the catalyst and concentrating the remaining solution gave 1.8 g of the desired cis configured, monoalkylated 1,3-cyclohexanediol derivative as an oil which crystallized when DIPE was added; yield 1.6 g; mp 81-82"C; H NMR (CDCl3), 8 = 1.25-2.14 (m, 9H), 3.63 (m, 1H), 3.75 (m, 1H), 4.55 (dd, 2H), 25 7.13 (m, 2H), 7.64 (s, 1H), 8.02 (m, 2H); MS (DCI): 292.3 (100%). Example 35 Synthesis of methyl (1R,3S)-2-{3-[2-(4-fluorophenyl)oxazol-4-ylmethoxy] cyclohexyl-1 -oxymethyl}-6-methylbenzoate 30 FO., O F .aCDCO 2 Me 43 0.8 g (2.75 mmol) of (1R,3S)-3-[2-(4-fluorophenyl)oxazol-4-ylmethoxy] cyclohexanol (from Example 34) was taken up in 10 ml of tBuOMe, admixed with 0.78 g (6.95 mmol) of KOtBu and stirred at 22-27*C for approx. 30 minutes. The mixture was cooled to 0-5*C, 1.24 g (approx. 94%, 5 approx. 4.8 mmol) of methyl 2-bromomethyl-6-methylbenzoate were added dropwise, the mixture was stirred initially at 30C for 2 hours and at 20*C for a further hour. The mixture is left to stir overnight at 18-21*C, then the solvent is distilled off. The residue is partitioned between water and tBuOMe. The organic phase is dried (Na2SO4) and concentrated under 10 reduced pressure; yield: 1.04 g of methyl (1R,3S)-2-{3-[2-(4 fluorophenyl)oxazol-4-ylmethoxy]cyclohexyl-1 -oxymethyl}-6-methyl benzoate as a yellowish oil; H NMR (CDCI3), 8 = 1.15-1.32 (m, 4H), 1.82 (m, 1H), 1.98-2.1 (m, 2H), 2.34 (s, 3H), 2.50 (m, 1H), 3.27 (m, 1H), 3.39 (m, 1H), 3.90 (s, 3H), 4.54 (s, 2H), 4.60 (s, 2H), 7.11-7.30 (m, 5H), 7.63 (s, 1H), 15 8.02 (m, 2H). Example 36 Synthesis of (1S,3R)-4-(3-benzyloxy-cyclohexyl-1 -oxymethyl)-2-(3 methoxyphenyl)-5-methyloxazole 20 MeO N 0 INN 4.6 g (22.3 mmol) of (1S,3R)-3-benzyloxycyclohexan-1 -ol were dissolved in 70 ml of chlorobenzene. 6.6 g (58.8 mmol) of KOtBu were added, the 25 mixture was stirred at 22*C for 30 minutes and then 10.3 g (31.3 mmol) of 4-iodomethyl-2-(3-methoxyphenyl)-5-methyloxazole were added. The temperature rose to 350C. The reaction was cooled slightly and stirred at 22-23*C for a further 2 hours. After the chlorobenzene had been distilled off under reduced pressure, the residue was partitioned between tBuOMe and 30 water. The organic phase was dried (Na 2
SO
4 ) and concentrated under reduced pressure; crude yield: 10.6 g. The substance was used in the next reaction (hydrogenation, see Example 37) without further purification.
44 Example 37 Synthesis of (1 R,3S)-3-[2-(3-methoxyphenyl)oxazol-4-ylmethoxy] cyclohexanol by hydrogenation 0 MeO 0, ,OH 5 10.5 g of (1S,3R)-4-(3-benzyloxycyclohexyl-1-oxymethyl)-2-(3-methoxy phenyl)oxazole were dissolved in approx. 120 ml of methanol, admixed with 2 g of Pd/C (10%, having 50% of water) and hydrogenated at 20-23*C under atmospheric pressure overnight. Filtering off the catalyst and 10 concentrating the remaining solution, partitioning between MTB ether and water and drying the organic phase gave 6.4 g of the desired cis configured, monoalkylated 1,3-cyclohexanediol derivative as a yellow oil. 1 g of the substance was chromatographed on silica gel (ethyl acetate): 0.8 g of a colorless oil were obtained; 1 H NMR (CDCl 3 ), 8 = 1.25-1.90 (m, 7 15 H), 2.12 (m, 1 H), 2.41 (s, 3 H), 3.61 (m, 1 H), 3.75 (m, 1H), 3.87 (s, 3 H), 4.48 (dd, 2 H), 6.96 (d, 1 H), 7.33 (t, 1 H), 7.53 (s, 1 H), 7.58 (d, 1 H); MS (ES+): 318.27 (83%), 243.18 (100 %). Example 38 20 Synthesis of methyl (1 R,3S)-2-{3-[2-(3-methoxyphenyl)-5-methyloxazol-4 ylmethoxy]cyclohexyl-1-oxymethyl}-6-methylbenzoate MeO O,, 0
CO
2 Me 25 136 mg (0.4 mmol) of (1 R,3S)-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-yl methoxy]cyclohexanol (from Example 37, hydrogenation) were dissolved in 1 ml of chlorobenzene, admixed at 24-27 0 C with 120 mg (1.07 mmol) of KOtBu and stirred for approx. 30 minutes. The mixture was cooled to 0 5*C, 189 mg (approx. 94%, approx. 0.78 mmol) of methyl 2-bromomethyl 30 6-methylbenzoate were added dropwise and the mixture was stirred at 0 5 0 C for an initial 30 minutes. Without further cooling, the reaction mixture had a temperature of approx. 20*C after 1.5 hours. After leaving to stand 45 overnight and adding approx. 20 mg of KOtBu, the reaction was complete after a further hour of stirring at 220C. Distilling off the chlorobenzene under reduced pressure, partitioning the residue between water and tBuOMe and drying the product-containing organic phase gave, after concentrating 5 under reduced pressure, 160 mg of methyl (1 R,3S)-2-{3-[2-(3 methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl-1 -oxymethyl}-6 methylbenzoate as a yellowish oil; 'H NMR (CDCl 3 ), 6 = 1.15-1.32 (m, 4 H), 1.81 (m, 1 H), 2.00 (m, 1 H), 2.06 (m, 1 H), 2.34 (s, 3 H), 2.40 (s, 3 H), 2.51 (m, 1 H), 3.27 (m, 1H), 3.36 (m, 1H), 3.87 (s, 3 H), 3.90 (m, 3 H), 4.48 10 (s, 2 H), 4.60 (s, 2 H), 6.96 (m, 1 H), 7.12-7.35 (m, 4 H), 7.53-7.60 (m, 2 H). Scheme 1lIb 15 Example 39 Synthesis of mono(3-benzyloxycyclohexyl) glutarate HO O,,~ O 0 0 rac. 20 3.0 g of 3-benzyloxycyclohexan-1-ol, 2.15 g of glutaric anhydride and 3.03 g of triethylamine were stirred at 21-23*C in 25 ml of methylene chloride. After complete conversion, the mixture was added to water, extracted, and dried over MgSO4. After concentrating under reduced pressure, 4.3 g of the desired compound were obtained; 1H NMR (CDCl 3 ), 25 8 = 1.20-1.28 (m, 4H), 1.82 (m, 1H), 1.90-1.97 (m, 3H), 2.05 (m, 1H), 2.32-2.42 (m, 5H), 3.39 (m, 1H), 4.55 (dd, 2H), 4.69 (m, 1H), 7.25-7.33 (m, 5H), 8.7 (br., 1H). Example 40 30 Stereoselective hydrolysis of mono(3-benzyloxycyclohexyl) glutarate, preparation of (1R,3S)-3-benzyloxycyclohexan-1-ol 46 HO 0 20 mg of racemic mono(3-benzyloxycyclohexyl) glutarate (from Example 39) were partitioned into 2 ml of phosphate buffer, pH 8, and 3-5 5 drops of DME, admixed with 3-5 mg of Novozyme 435 and stirred at 21-23*C. After approx. 50% conversion, the reaction solution was partitioned between saturated aqueous NaHCO 3 solution and ethyl acetate. The ethyl acetate phase was dried and concentrated, yield: 5 mg of (1 R,3S)-3-benzyloxycyclohexan-1-ol, and the enantiomeric excess was 10 > 95% (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA). Example 41 Synthesis of (1R,3S)-4-(3-benzyloxycyclohexyl-1-oxymethyl)-2-(4-fluoro 15 phenyl)oxazole N FOO Starting from (1R,3S)-3-benzyloxycyclohexan-1-oI (see Example 40), 20 alkylation with 4-iodomethyl-2-(4-fluorophenyl)oxazole (see Example 32) results in (1 R,3S)-4-(3-benzyloxycyclohexyl-1 -oxymethyl)-2-(4-fluoro phenyl)oxazole, cf. Example 33. Further examples of the alkylation of cis-1,3-cyclohexanediol 25 Example 42 Synthesis of racemic methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate 47 HO,, ~ O rac. CO 2 Me 5 g (42.8 mmol) of cis-1,3-cyclohexanediol were dissolved in 50 ml of dimethoxyethane (DME), admixed at 20-23*C with 3.36 g (30 mmol) of 5 potassium tert-butoxide (KOtBu) and stirred. After about 30 minutes, the mixture is cooled to 5*C and 3.7 g (approx. 50%) of methyl 2-bromomethyl 6-methylbenzoate, which may be prepared, for example, by methanolyzing the acid bromide (2-bromomethyl-6-methylbenzoyl bromide) or by brominating methyl 2,6-dimethylbenzoate, are added dropwise. The 10 mixture is stirred at 5-10*C for 1 h and then at 20-23 0 C overnight. Water and methyl tert-butyl ether (MTBE) are added, the mixture is stirred vigorously, the phases are separated, the aqueous phase is washed once more with MTBE and the combined organic phases are concentrated under reduced pressure. The residue is chromatographed on silica gel (1:1 ethyl 15 acetate/n-heptane). 600 mg of the desired compound are obtained as a light yellow oil, H NMR (CDCl3), 6 = 1.27 (m, 1H), 1.45 (m, 1H), 1.55 (m, 1H), 1.74 (m, 1H), 1.83 (m, 1H), 2.05 (m, 1H), 2.34 (s, 3H), 3.47 (m, 1H), 3.72 (m, 1H), 3.91 (s, 3H), 4.58 (dd, 2H), 7.15 (d, 1H), 7.20 (d, 2H), 7.27 (m, 1H). 20 Example 43 Synthesis of racemic methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate HO,,, ,O rac. CO 2 Me 25 10.0 g (86 mmol) of cis-1,3-cyclohexanediol were taken up in 150 ml of methyl tert-butyl ether (MTBE), admixed at approx. 20 0 C with 6.72 g (59.9 mmol) of potassium tert-butoxide (KOtBu) and stirred. After about 30 30 minutes, the suspension was cooled to 5 0 C and admixed dropwise with 7.4 g (approx. 50%) of methyl 2-bromomethyl-6-methylbenzoate, which 48 may be prepared, for example, by methanolyzing the acid bromide (2-bromomethyl-6-methylbenzoyl bromide) or by brominating methyl 2,6-dimethylbenzoate. The mixture was stirred at 0-5 0 C for 1 h, heated to 20-23*C and left to stir overnight. Water was added, the mixture was stirred 5 vigorously, the phases were separated, the organic phase was washed once more with water and then the organic phase was concentrated under reduced pressure. The residue (4.6 g) was chromatographed on silica gel (1:1 ethyl acetate/n-heptane). 1.2 g of the desired compound were obtained as a light yellow oil, H NMR (CDCl3), 5 = 1.27 (m, 1H), 1.45 (m, 1H), 1.55 10 (m, 1H), 1.74 (m, 1H), 1.82 (m, 1H), 2.05 (m, 1H), 2.34 (s, 3H), 3.46 (m, 1H), 3.72 (m, 1H), 3.91 (s, 3H), 4.58 (dd, 2H), 7.15 (d, 1H), 7.20 (d, 2H), 7.27 (m, 1H). Example 44 15 Synthesis of racemic methyl cis-2-(3-hydroxycyclohexyloxymethyl) 6-methylbenzoate HO,,,O CO 2 Me rac. 20 5 g (42.8 mmol) of cis-1,3-cyclohexanediol were dissolved in 40 ml of chlorobenzene and 10 ml of 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H) pyrimidinone (DMPU, dimethylpropyleneurea), admixed at 20-23 0 C with 3.36 g (30 mmol) of potassium tert-butoxide (KOtBu) and stirred. After 10 15 minutes, the mixture was cooled to 15-20*C and 3.7 g (approx. 50%) of 25 methyl 2-bromomethyl-6-methylbenzoate were added dropwise. The mixture was stirred at 20 0 C for 1.5 h and then added to water. The organic phase was removed and concentrated under reduced pressure. The residue was taken up in NMP/water and, to remove impurities, washed twice with n-heptane. Subsequently, the product was isolated by extracting 30 twice with MTBE. The combined MTBE phases were washed with water, dried (Na 2
SO
4 ) and concentrated under reduced pressure. The residue (1.2 g) was chromatographed on silica gel (1:1 ethyl acetate/n-heptane). 580 mg of the desired compound were obtained as a slightly yellow oil; 1 H NMR (CDCl 3 ), 5 = 1.27 (m, 1 H), 1.45 (m, 1 H), 1.55 (m, 1 H), 1.74 (m, 1 49 H), 1.83 (m, 1 H), 2.05 (m, 1 H), 2.34 (s, 3 H), 3.47 (m, 1 H), 3.72 (m, 1 H), 3.91 (s, 3 H), 4.58 (dd, 2 H), 7.15 (d, 1 H), 7.20 (d, 2 H), 7.27 (m, 1H). Further examples of the optical resolution by stereoselective ester 5 formation (EF) Example 45 Optical resolution of methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate 10 HO,,, O rac. CO 2 Me 730 mg of the racemic methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate are dissolved in 5 ml of methylene chloride and 2 ml of 15 vinyl acetate, heated to 380C and admixed with 100 mg of Novozyn 435. After approx. 5 h, the reaction was ended by filtering off the enzyme and the optical purity of the acetate formed and of the unconverted alcohol were determined by HPLC (HPLCacetate:Chiralcel OD 250 x 4.6, 1 ml/min, 100:1:0.5 heptane/EtOH/CH3CN; HPLCalcohol:ChiralpakAD 250 x4.6; 20 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN +0.1% TFA). The determination of the optical purity for methyl (3S,1R)-2-(3-hydroxycyclohexyl-1 oxymethyl)-6-methylbenzoate gave 98% ee and 86% ee for the (3R,1S) acetate. 25 Example 46 Optical resolution of methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate H,,o,,, o0 rac. CO 2 Me 30 20 mg of the racemic methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate were dissolved in 2 ml of chlorobenzene and 1 ml of vinyl 50 acetate, admixed at 22-25 0 C with 8 mg of Chirazyme L-2, lyo. (Roche), and stirred. After approx. 6 h, the reaction was ended by filtering off the enzyme and the optical purity of the acetate formed and of the unconverted alcohol were determined by HPLC (HPLCacetate:Chiralcel OD 250 x 4.6, 1 ml/min, 5 100:1:0.5 heptane/EtOH/CH 3 CN; HPLCalcohol:Chiralpak AD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA) were determined: 84% ee of methyl (3S, 1 R)-2-(3-hydroxycyclohexyl-1 -oxymethyl)-6 methylbenzoate and 95% ee of the (3R, 1 S)-acetate. 10 Example 47 Optical resolution of methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate rac. CO 2 Me 15 1.0 g of methyl cis-2-(3-hydroxycyclohexyl- 1 -oxymethyl)-6-methylbenzoate were dissolved in 10 ml of 1,2-dichloroethane and 2 ml of vinyl propionate, admixed with 25 mg of Chirazyme L-2, lyo. (Roche) and stirred at 21-24*C for 40 h. Filtering off the enzyme, concentrating the filtrate under reduced 20 pressure and chromatography of the residue on silica gel (1:1 ethyl acetate/n-heptane) gave 0.49 g of the (3R,1S)-propionate having 92% ee (HPLC on Chiralcel OD 250 x 4,6, 1 ml/min, 100:1:0.5 heptane/ EtOH/CH3CN), H NMR (CDCl 3 ), 8 = 1.13 (t, 3H), 1.15-1.36 (m, 4H), 1.79 (m, 1H), 1.91 (m, 1H), 2.01 (m, 1H), 2.30 (q, 2H), 2.34 (s, 3H), 2.35 (m, 25 1H), 3.34 (m, 1H), 3.90 (s, 3H), 4.58 (dd, 2H), 4.67 (m, 1H), 7.14 (d, 1H), 7.19 (d, 1H), 7.26 (m, 1H), and also 0.3 g of the unconverted methyl (3S, 1 R)-2-(3-hydroxycyclohexyl-1 -oxymethyl)-6-methylbenzoate having 98% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA), H NMR (CDCl 3 ), 8 = 1.27 (m, 1H), 30 1.45 (m, 1H), 1.55 (m, 1H), 1.74 (m, 1H), 1.83 (m, 1H), 2.05 (m, 1H), 2.34 (s, 3H), 3.47 (m, 1H), 3.72 (m, 1H), 3.91 (s, 3H), 4.58 (dd, 2H), 7.15 (d, 1H), 7.20 (d, 2H), 7.27 (m, 1H).
51 Example 48 Optical resolution of methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate HO,,, ,0 rac. CO 2 Me 5 10 mg of the racemic methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate were dissolved in 1 ml of vinyl acetate, admixed with approx. 4-6 mg of Lipase TL (Pseud. stutzeri, Meito Sangyo) and stirred at 10 22-25*C. After > 50% conversion, the reaction was ended by filtering off the enzyme and the optical purity of the unconverted methyl (3S,1R)-2-(3 hydroxycyclohexyl-1 -oxymethyl)-6-methylbenzoate was determined: > 98% ee (HPLC on Chiralpak AD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA). 15 Example 49 Optical resolution of methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate rac. CO 2 Me 20 3.9 g of the racemic methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate were dissolved in 25 ml of methylene chloride and 10 ml of vinyl acetate, heated to 45 0 C and admixed with 250 mg of Novozym 435. 25 After approx. 45% conversion, the reaction was ended by filtering off the enzyme and the reaction mixture was concentrated. Chromatography of the residue on silica gel (1:1 ethyl acetate/n-heptane) gave 1.9 g of the (3R,1S)-acetate (> 95% ee, HPLC on Chiralcel OD 250 x 4.6, 1 ml/min, 100:1:0.5 heptane/EtOH/CH 3 CN) and 1.9 g of the unconverted methyl 30 (3S,1R)-2-(3-hydroxycyclohexyl-1-oxymethyl)-6-methylbenzoate (82% ee, HPLC on Chiralpak AD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA).
52 Example 50 Optical resolution of methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate HO,, O rac. CO 2 Me 5 20 mg of the racemic methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate were dissolved in 2 ml of toluene and 1 ml of vinyl acetate, admixed at 20-23*C with 6-8 mg of Chirazyme L-2, lyo. (Roche), and 10 stirred. After approx. 45% conversion, the reaction was ended by filtering off the enzyme and the optical purity of the (3R,1S)-acetate formed was determined: 94% ee (HPLC on Chiralcel OD 250 x 4.6, 1 ml/min, 100:1:0.5 heptane/EtOH/CH3CN). 15 Example 51 Optical resolution of methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate rac.
CO
2 Me 20 10 mg of the racemic methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate were dissolved in 1 ml of vinyl acetate, admixed with approx. 4-6 mg of Lipase QL (Alcaligenes spec., Meito Sangyo) and stirred at 20-23 0 C. After approx. 52% conversion, the reaction was ended by 25 filtering off the enzyme and the optical purity of the acetate formed and of the unconverted alcohol were determined, ee of the acetate: 91% (HPLC on Chiralcel OD 250 x 4.6, 1 ml/min, 100:1:0.5 heptane/EtOH/CH3CN), ee of the methyl (3S, 1 R)-2-(3-hydroxycyclohexyl-1 -oxymethyl)-6-methyl benzoate: > 98% ee (HPLC on Chiralpak AD 250 x 4.6; 1 ml/min, 25:1:0.5 30 heptane/EtOH/CH3CN + 0.1% TFA).
53 Example 52 Optical resolution of methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate HO,,, so rac. CO 2 Me 5 10 mg of the racemic methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate were dissolved in 1 ml of vinyl acetate, admixed with approx. 4-6 mg of Lipase SL (Pseud. cepacia, Meito Sangyo) and stirred at 10 20-23*C. After approx. 52% conversion, the reaction was ended by filtering off the enzyme and the optical purity of the acetate formed and of the unconverted alcohol were determined, ee of the acetate: 90% (HPLC on Chiralcel OD 250 x 4.6, 1 ml/min, 100:1:0.5 heptane/EtOH/CH 3 CN), ee of the methyl (3S,1R)-2-(3-hydroxycyclohexyl-1-oxymethyl)-6-methyl 15 benzoate: > 95% ee (HPLC on Chiralpak AD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA). Example 53 Optical resolution of methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 20 methylbenzoate rac. CO 2 Me 39 g of methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6-methylbenzoate 25 were dissolved in 250 ml of methylene chloride and 50 ml of vinyl acetate, heated to 45 0 C and admixed with 1.0 g of Novozym 435. After 25 h, a further 0.5 g of Novozym 435 was added. After a further 6.5 hours, the enzyme was filtered off and . the reaction mixture concentrated. Chromatography of the residue on 630 g of silica gel (1:1 ethyl 30 acetate/n-heptane) gave 18.2 g of methyl (3S, 1 R)-2-(3-hydroxycyclohexyl 1-oxymethyl)-6-methylbenzoate (> 98% ee, HPLC on Chiralpak AD-H 54 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA), 1H NMR (CDCl 3 ), 8 = 1.27 (m, 1H), 1.45 (m, 1H), 1.55 (m, 1H), 1.74 (m, 1H), 1.83 (m, 1H), 2.05 (m, 1H), 2.34 (s, 3H), 3.47 (m, 1H), 3.72 (m, 1H), 3.91 (s, 3H), 4.58 (dd, 2H), 7.15 (d, 1H), 7.20 (d, 2H), 7.27 (m, 1H). 5 Example 54 Optical resolution of methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate HO0,,.C , 0O rac. CO 2 Me 10 20 mg of the racemic methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate were dissolved in 2 ml of THF and 1 ml of vinyl acetate, admixed at 20-23"C with 6-8 mg of Chirazyme L-2, lyo. (Roche), and 15 stirred. After approx. 6 h, the reaction was ended by filtering off the enzyme and the optical purity of the acetate formed and of the unconverted alcohol were determined by HPLC (HPLCacetate:Chiralcel OD 250 x 4.6, 1 ml/min, 100:1:0.5 heptane/EtOH/CH 3 CN; HPLCalcohol:Chiralpak AD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA): ee of the methyl 20 (3S,1R)-2-(3-hydroxycyclohexyl-1-oxymethyl)-6-methylbenzoate 89% and ee of the (3R,1S)-acetate 95% and Example 55 Optical resolution of methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 25 methylbenzoate HO,, Me rac. CO 2 Me Approx. 15 mg of the racemic methyl cis-2-(3-hydroxycyclohexyl-1 30 oxymethyl)-6-methylbenzoate were dissolved in 2 ml of tert-butanol and 1 ml of vinyl acetate, admixed at 20-23*C with approx. 6 mg of 55 Novozym 435 and stirred. After approx. 24 h, the reaction was ended by filtering off the enzyme and the optical purity of the acetate formed and of the unconverted alcohol were determined by HPLC: (3R,1S)-acetate 91% ee (HPLC: Chiralcel OD 250 x 4.6, 1 ml/min, 100:1:0.5 5 heptane/EtOH/CH3CN), methyl (3S,1R)-2-(3-hydroxycyclohexyl-1 oxymethyl)-6-methylbenzoate 96% ee (HPLC: Chiralpak AD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA). Example 56 10 Optical resolution of methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6 methylbenzoate HO,,,0.,,0 rac. CO 2 Me 15 10 mg of the racemic methyl cis-2-(3-hydroxycyclohexyl-1-oxymethyl)-6 methylbenzoate were dissolved in 1 ml of vinyl acetate, admixed with approx. 4-6 mg of Lipase TL (Pseud. stutzeri, Meito Sangyo) and stirred at 20-23*C. After > 50% conversion, the reaction was ended by filtering off the enzyme and the optical purity of the unconverted alcohol was determined: 20 methyl (3S,1 R)-2-(3-hydroxycyclohexyl-1-oxymethyl)-6-methylbenzoate > 98% ee (HPLC on Chiralpak AD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA). Example 57 25 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,, O0 -0 rac. 35-40 mg of racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 30 0.5-1 ml of vinyl acetate and 2-3 ml of methylene chloride, admixed with approx. 8-10 mg of Novozym 435 and stirred at 22-25*C. After 4 days, the reaction was ended by filtering off the enzyme. The optical purity of the 56 alcohol, (1S,3R)-3-benzyloxycyclohexan-1-ol, was > 98% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH.CH 3 CN + 0.1% TFA), and the ee of the (1R,3S)-acetate was 82% (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 100:1:0.5 heptane/EtOH/CH 3 CN). 5 Example 58 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,, O rac. 10 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of THF, admixed with approx. 5 mg of Lipase L-1 0 and stirred at 22-25*C. After 50% conversion, the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3 15 benzyloxycyclohexan-1-ol was !90% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA). Example 59 Optical resolution of cis-3-benzyloxycyclohexan-1-ol 20 HO,. 0 rac. 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of chlorobenzene, admixed with 10 mg of 25 Novozym 435 and stirred at 22-25*C. After 4 hours, the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3 benzyloxycyclohexanol was 68% ee (HPLC on Chiralpak AD-H 250 x 4.6, 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA), and the ee of the enantiomeric acetate was 95% (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 30 100:1:0.5 heptane/EtOH/CH3CN).
57 Example 60 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,, O rac. 5 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of cyclohexane, admixed with approx. 5 mg of Lipase QL and stirred at 22-25 0 C. After 24 hours, the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3 10 benzyloxycyclohexan-1-ol was 94% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA). Example 61 Optical resolution of cis-3-benzyloxycyclohexan-1-ol 15 HO, o0 rac. 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of toluene, admixed with 10 mg of 20 Novozym 435 and stirred at 22-25 0 C. After 4 hours, the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3 benzyloxycyclohexan-1-ol was 70% ee (HPLC on Chiralpak AD-H 250 x 4.6, 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA), and the ee of the (1 R,3S)-acetate was 95% (HPLC on Chiralcel OD 250 x 4.6; 25 1 ml/min, 100:1:0.5 heptane/EtOH/CH3CN). Example 62 Optical resolution of cis-3-benzyloxycyclohexan-1-ol 58 HO,,, ,O rac. 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of cyclohexane, admixed with approx. 10 mg 5 of Novozym 435 and stirred at 22-25*C. After approx. 4 hours, the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3 benzyloxycyclohexan-1-ol was 95% ee (HPLC on Chiralpak AD-H 250 x 4.6, 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA), and the ee of the (1 R,3S)-acetate was 90% (HPLC on Chiralcel OD 250 x 4.6; 10 1 ml/min, 100:1:0.5 heptane/EtOH/CH 3 CN). Example 63 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,. O rac. 15 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of cyclohexane, admixed with approx. 5 mg of Lipase L-10 and stirred at 22-25'C. After 24 hours, the reaction was 20 ended by filtering off the enzyme. The optical purity of (1S,3R)-3 benzyloxycyclohexan-1-ol was > 95% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA). Example 64 25 Optical resolution of cis-3-benzyloxycyclohexan-1-ol H0,,, . 0 rac.
59 Approx. 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of THF, admixed with 10 mg of Novozym 435 and stirred at 22-25*C. After 4 hours, the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3-benzyloxy 5 cyclohexanol was 73% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA), and the ee of the (1R,3S) acetate was 94% (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 100:1:0.5 heptane/EtOH/CH3CN). 10 Example 65 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO, O rac. 15 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of chlorobenzene, admixed with approx. 5 mg of Lipase L-10 and stirred at 22-25*C. After > 50% conversion, the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3 benzyloxycyclohexan-1-ol was 92% ee (HPLC on Chiralpak AD-H 20 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA). Example 66 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,,, O, 25 rac. Approx. 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of ethyl acetate, admixed with approx. 10 mg of Novozym 435 and stirred at 22-25 0 C. After 4 hours, the 30 reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3-benzyloxycyclohexan-1-ol was 77% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 60 0.1% TFA), and the ee of the (1R,3S)-acetate was 93% (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 100:1:0.5 heptane/EtOH/CH 3 CN). Example 67 5 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,, ,0O rac. 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 10 1 ml of vinyl acetate and 3 ml of chlorobenzene, admixed with approx. 5 mg of Lipase SL and stirred at 22-25 0 C. After 50% conversion, the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3 benzyloxycyclohexan-1-ol was 87% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA). 15 Example 68 Optical resolution of cis-3-benzyloxycyclohexan-1-ol rac. 20 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of diisopropyl ether, admixed with 10 mg of Novozym 435 and stirred at 22-25*C. After 4 hours, the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3-benzyloxy 25 cyclohexan-1-ol was 90% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 mI/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA), and the ee of the (1 R,3S)-acetate was 90% (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 100:1:0.5 heptane/EtOH/CH3CN). 30 Example 69 Optical resolution of cis-3-benzyloxycyclohexan-1-ol 61 HO,, , .O rac. 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of MTBE, admixed with 10 mg of 5 Novozym 435 and stirred at 22-25 0 C. After 4 hours, the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3-benzyloxy cyclohexan-1-ol was 93% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA), and the ee of the (1 R,3S)-acetate was 89% (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 10 100:1:0.5 heptane/EtOH/CH3CN). Example 70 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,,, _0 rac. 15 10 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 1 ml of vinyl acetate and 3 ml of cyclohexane, admixed with approx. 5 mg of Lipase SL and stirred at 22-25*C. After 24 hours, the reaction was ended 20 by filtering off the enzyme. The optical purity of (1S,3R)-3-benzyloxy cyclohexan-1-ol was > 90% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA). Example 71 25 Optical resolution of cis-3-benzyloxycyclohexan-i-ol HO,, O rac.
62 27 mg of racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 3 ml of methylene chloride, admixed with 65 mg of isovaleric anhydride and with 11 mg of Novozyme 435 and stirred at 22-25 0 C. After 45-50% conversion, 5 the reaction was ended by filtering off the enzyme. The optical purity of (1S,3R)-3-benzyloxycyclohexan-1-ol was 87% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA), and the enantiomeric excess of the (1 R,3S)-isovaleric acid derivative was >95% (HPLC on Chiralcel OD 250 x4.6; 1 ml/min, 100:1:0.5 10 heptane/EtOH/CH3CN). Example 72 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,, , O rac. 15 200 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 3 ml of chlorobenzene, admixed with 100 mg of succinic anhydride and 10 mg of Chirazyme L-2, Iyo., and stirred at 25-27 0 C. After 29 hours, the 20 reaction was ended by filtering off the enzyme. A sample which had been concentrated by evaporation was used to determine the optical purity both of the unconverted substrate and of the acylation product formed. The optical purity of (1S,3R)-3-benzyloxycyclohexan-1-o was > 98% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 25 0.1% TFA), and the optical purity of the succinic acid derivative was 94% ee (HPLC on Chiralcel OD 250 x 4.6; 1 mI/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA).
63 Example 73 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,, O rac. 5 200 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 3 ml of DME, admixed with 100 mg of succinic anhydride and 10 mg of Chirazyme L-2, lyo., and stirred at 25-27*C. After 29 hours, the reaction was ended by filtering off the enzyme. A sample which had been 10 concentrated by evaporation was used to determine the optical purity both of the unconverted substrate and of the acylation product formed. The optical purity of (1S,3R)-3-benzyloxycyclohexan-1-ol was > 95% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA), and the optical purity of the succinic acid derivative was 15 > 97% ee (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA). Example 74 Optical resolution of cis-3-benzyloxycyclohexan-1-ol 20 HO, 1O rac. 200 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 3 ml of THF, admixed with 100 mg of succinic anhydride and 10 mg of 25 Chirazyme L-2, lyo., and stirred at 25-27*C. After 29 hours, the reaction was ended by filtering off the enzyme. A sample which had been concentrated by evaporation was used to determine the optical purity both of the unconverted substrate and of the acylation product formed. The optical purity of (1S,3R)-3-benzyloxycyclohexan-1-ol was 84% ee (HPLC 30 on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA), and the optical purity of the succinic acid derivative was 64 > 95% ee (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA). Example 75 5 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,, *O rac. 200 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 10 3 ml of methylene chloride, admixed with 100 mg of succinic anhydride and 10 mg of Chirazyme L-2, lyo., and stirred at 25-27 0 C. After 29 hours, the reaction was ended by filtering off the enzyme. A sample which had been concentrated by evaporation was used to determine the optical purity both of the unconverted substrate and of the acylation product formed. The 15 optical purity of (1S,3R)-3-benzyloxycyclohexan-1-ol was > 98% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA), and the optical purity of the succinic acid derivative was 88% ee (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA). 20 Example 76 Optical resolution of cis-3-benzyloxycyclohexan-1-ol HO,. .O rac. 25 200 mg of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 3 ml of acetone, admixed with 100 mg of succinic anhydride and 10 mg of Chirazyme L-2, lyo., and stirred at 25-27*C. After 29 hours, the reaction was ended by filtering off the enzyme. A sample which had been 30 concentrated by evaporation was used to determine the optical purity both of the unconverted substrate and of the acylation product formed. The optical purity of (1S,3R)-3-benzyloxycyclohexan-1-o was > 99% ee (HPLC 65 on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA), and the optical purity of the succinic acid derivative was 78% ee (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA). 5 Example 77 Optical resolution of cis-3-benzyloxycyclohexan-1-ol, separation of alcohol and succinic acid derivative HO,, ,O rac. 10 8.15 g (39.5 mmol) of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 120 ml of THF, admixed with 3.9 g (39.0 mmol) of succinic anhydride and 390 mg of Chirazyme L-2, lyo., and stirred at 22-25 0 C. After 15 approx. 40% conversion, the reaction was ended by filtering off the enzyme. The filtrate was concentrated under reduced pressure. The residue was taken up with tBuOMe and extracted intensively three times with in each case 100 ml of sat. aqueous NaHCO 3 solution. The organic phase was dried (MgSO 4 ) and concentrated under reduced pressure; 20 yield: 4.4 g; the optical purity of (1S,3R)-3-benzyloxycyclohexan-1-ol was 70% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH3CN + 0.1% TFA). The optical purity of the succinic acid derivative dissolved in the combined aqueous phases was > 99% ee (HPLC on Chiralcel OD 250 x 4.6; 1 ml/min, 25:1:0.5 25 heptane/EtOH/CH3CN + 0.1% TFA). By treating with conc. sodium hydroxide solution, the aqueous solution of the succinic acid derivative was hydrolyzed chemically. The (1R,3S)-3 benzyloxycyclohexan-1-ol formed was extracted with tBuOMe; yield: 2.9 g. 30 Example 78 Optical resolution of cis-3-benzyloxycyclohexan-1-ol, separation of alcohol and succinic acid derivative 66 HO,, O rac. 5.06 g (24.5 mmol) of the racemic cis-3-benzyloxycyclohexan-1-ol were dissolved in 75 ml of THF, admixed with 2.52 g (25.2 mmol) of succinic 5 anhydride and 3.1 g of Novozym 435, and stirred at 22-25*C. After 28.5 h, the reaction was ended by filtering off the enzyme. The filtrate was concentrated down to approx. 15 ml under reduced pressure. The residue was admixed with 30 ml of water and the remaining THF was distilled off under reduced pressure. 15 ml of saturated aqueous NaHCO 3 solution, 15 10 ml of water and 30 ml of methylene chloride were added and the mixture was stirred intensively for 15-30 min. After phase separation, the organic phase was extracted first with 90 ml of saturated aqueous NaHCO 3 solution and 150 ml of water, and then with 15 ml of saturated aqueous NaHCO 3 solution and 30 ml of water, and washed twice with 30 ml of water. The 15 organic phase was dried (MgSO 4 ) and concentrated under reduced pressure; yield: 2.52 g (50%), [a]" +12.1* (c = 1.0, MeOH); the optical purity of (1S,3R)-3-benzyloxycyclohexan-1-ol was > 99% ee (HPLC on Chiralpak AD-H 250 x 4.6; 1 ml/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% TFA). 20 The combined aqueous phases were admixed with 20 ml of (glacial) acetic acid and extracted twice with 20 ml of methylene chloride. The organic phase was dried (MgSO 4 ) and concentrated; yield: 3.55 g (47%) of the succinic acid derivative; the optical purity was > 99% ee (HPLC on Chiralcel OD 250 x 4.6; 1 mI/min, 25:1:0.5 heptane/EtOH/CH 3 CN + 0.1% 25 TFA); 'H NMR (CDCl 3 ) 8: 1.2-1.43 (m, 4H), 1.82 (m, 1H), 1.93 (m, 1H), 2.04 (m, 1H), 2.40 (m, 1H), 2.58-2.70 (m, 4H), 3.39 (m, 1H), 4.54 (m, 2H), 4.71 (m, 1H); 7.23-7.36 (m, 5H). Example 79 30 Preparation of racemic cis-3-(tert-butyldimethylsilanyloxy)cyclohexanoI HO. ,,OSiMe 2 tBu rac 67 TBDMSCI (28.62 g, 1.1 eq) was added slowly to a solution, cooled to 100C, of 1,3-cyclohexanediol (20.05 g, 0.173 mol), Et 3 N (28.79 ml, 1.2 eq) and DMAP (0.844 g, 0.04 eq) in CH 2
CI
2 (600 ml). After stirring at 20-23*C for 18 5 hours, the reaction mixture was washed with H 2 0 (2 x 100 ml). The organic phase was washed with sat. NH 4 CI (2 x 100 ml), dried over MgSO 4 and concentrated under reduced pressure. Chromatography on silica gel, (20:1 n-heptane/ethyl acetate) gave 18.77 g (47%) of the desired monsilyl ether; 1 H NMR (CDCl 3 ) 8: 0.0-0.1 (m, 6H), 0.8-0.9 (m, 9H), 1.2-2.0 (m, 8H), 3.2 (s, 10 br., 1H), 3.8 (m, 1H), 3.95 (m, 1H). Example 80 Preparation of cis-(1S, 3R)-3-(tert-butyldimethylsilanyloxy)cyclohexanol HO ,,OSiMe 2 tBu 15 770 mg of racemic cis-3-(tert-butyldimethylsilanyloxy)cyclohexano were dissolved in 10 ml of acetone, admixed with 0.36 ml of vinyl acetate and 400 mg of Novozym 435 and stirred at 21-24*C. After 47 h (approx. 50% 20 conversion), the reaction was ended by filtering off the enzyme and the solution was concentrated by evaporation under reduced pressure. Chromatography of a portion of silica gel (3:1 n-heptane/ethyl acetate) gave (1S,3R)-3-(tert-butyldimethylsilanyloxy)cyclohexanoI having [a] * +12.80 (c = 1.0, MeOH). 25 Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.

Claims (7)

1. A process for preparing a chiral, nonracemic compound of the formula 1 5 RI (I) where: 10 R 1 is R4 0 R3 RingA N (CH 2 )n R5 where: 15 ring A is phenyl, 5-12 membered heteroaromatic ring which may contain from one to four heteroatoms from the group of N, 0 and S, 8 to 14 membered aromatic ring, (C3-C8)-cycloalkyl; R 3 is H, F, Cl, Br, OH, NO 2 , CF 3 , OCF3, (C1-C6)-alkyl, (C 3 -C 8 ) 20 cycloalkyl, phenyl; R 4 , R 5 are H, F, Cl, Br, OH, NO 2 , CF3, OCF 3 , OCF2H, OCF2-CF3, OCF2-CHF2, SCF3, 0-phenyl, (C1-C6)-alkyl, 0-(C1-C6)-alkyl, 0 (C 1 -C 6 )-alkyl-O-(C1-C3)-alkyl; 25 n is from 1 to 3; and 30 R2 is (C1-C8)-alkyl where one or more CH 2 groups in the alkyl groups may be replaced by 0, CO, S, SO or S02, and alkyl may be one to 69 trisubstituted by F, Cl, Br, CF3, CN, NO 2 , NHAc, NHBoc, NH-CO C(CH 3 ) 3 , hydroxyl, OCF 3 , O-(C 1 -C 6 )-alkyl, COOH, CO-benzoxy, CO-O(C1-C 6 )-alkyl, tetrazole, thiazolidine-2,4-dione, indole and (C6-Clo)-aryl, where thiazolidine-2,4-dione and aryl may in turn be 5 substituted by F, CI, Br, CF 3 , CN, NO 2 , NHAc, NHTs, NHBoc, NHCbz, NH-CO-C(CH3) 3 , hydroxyl, OCF 3 , 0-(C1-C6)-alkyl, COOH, CO-benzoxy, CO-O(C1-C6)-alkyl, (C1-C6)-alkyl, 0-(C1-C6)-alkyl or tetrazole, or; 10 R2 is an OH protecting group (PG), for example benzyloxymethyl, benzyl, para-methoxybenzyl or tert-butyldimethylsilyl; which comprises 15 A) a) alkylation (alk-R 2 /alk-PG) reacting cis-1,3-cyclohexanediol of the formula (11) HO, OH 20 with a compound of the formula (Ill) X -R() 25 where R 2 is as defined above and X 1 is CI, Br, I, OMs, OTs, OTf; 30 in the presence of bases in a suitable solvent to give a racemic compound of the formula (IV) HO,, o R2( V (IV) 70 where R 2 is as defined above; b1) enzymatic ester formation (EF) + separation (S) 5 subjecting the resulting compounds of the formula (IV) to stereoselective enzymatic ester formation (EF), in which the alcohols are admixed with an acyl donor and the enzyme in an organic solvent and the resulting mixture is stirred at -20 to 80 0 C and, after the reaction has ended, one stereoisomer is present as an ester of the formula (V) 10 R6O0R2 (V) where R6 is C(=O)-(C1-C16)-alkyl, C(=O)-(C2-C1 6 )-alkenyl, C(=O)-(C 3 -C 16 ) 15 alkynyl, C(=O)-(C3-C16)-cycloalky, where one or more carbon atoms may be replaced by oxygen atoms and be substituted by 1-3 substituents from the group of F, Cl, Br, CF 3 , CN, NO 2 , hydroxyl, methoxy, ethoxy, phenyl and CO-O(C1-C4)-alkyl, CO-O(C 2 -C 4 ) alkenyl, which may in turn be substituted by 1-3 substituents from 20 the group of F, Cl, Br, CF3, and R 2 is as defined above, and the other stereoisomer is present unchanged as the alcohol of the 25 formula (IV), and are therefore separated from each other by utilizing their different chemical or physicochemical properties (separation S) or 30 b2) enzymatic ester hydrolysis [=chemical esterification (CE) + enzymatic hydrolysis (EH)] + separation (S) subjecting the resulting compound of the formula (IV) to a stereoselective enzymatic ester hydrolysis, in which the racemic alcohol is initially 35 converted by chemical esterification (CE), for example by means of acid 71 chloride R 6 -CI or acid anhydride R-O- R , in the presence of bases, to the racemic ester of the formula (V) R6..--O,, Os1 R2 (V) 5 where R 6 and R 2 are each as defined above, which, to carry out the stereoselective enzymatic ester hydrolysis (EH), is then taken up in homogeneous or heterogeneous, aqueous, aqueous 10 organic or organic medium, and reacted, in the presence of an enzyme in the case of hydrolysis with water and in the case of alcoholysis with an alcohol, at a temperature of 10-80*C, and after the reaction has ended, one stereoisomer is present as the alcohol of the formula (IV) and the other is present unchanged as the ester of the formula (V) and can thus be 15 separated from each other as described under b1), and the enantiomer of the formula (IV) occurring as an alcohol is further processed as described under d), or 20 c) chemical hydrolysis (CH) hydrolyzing the enantiomer of the formula (V) occurring as an ester to the chemically enantiomeric alcohol by known methods and 25 d) alkylation (alk- R 1 ) reacting further with a compound of the formula (VI) R4 R3 Ring A (VI) N (CH 2 )n - X2 R5 30 where ring A, R 3 , R 4 , R 5 and n are each as defined above and 72 X2 is Cl, Br, I, OTs, OMs, OTf; in the presence of bases in a suitable solvent to give the compound of the 5 formula (I), and e) detachment of the protecting group PG (detPG) if R 2 is an OH protecting group (PG) as defined above under R 2 , converting 10 the compound of the formula (la) 0- " 01* R1 , PG (Ia) where R 1 and PG are each as defined above, 15 by detaching the protecting group by known methods to a compound of the formula (VII) OH R1 (VII) 20 where R 1 is as defined above, f) alkylation (alk- R 2 ) 25 then reacting it with a compound of the formula (Ill) 1 2(I) X -R2 where X 1 and R 2 are each as defined above, 30 in the presence of bases in a suitable solvent to give a compound of the formula (1), the product or the enantiomeric form, 73 it being also possible to change the sequence of individual reaction steps as described above under A): A) alk-R 2 -+ EF + S/CE + EH + S [-+ CH] -+ alk- R 1 [-+ DetPG -+ alk 5 R 2 ] -* product/enantiomeric form to: B) alk- R 1 -+ EF + S/CE + EH + S [-> CH] - alk- R 2 [- DetPG -+ alk 10 R 2 ] -> product/enantiomeric form or C) alk-PG -+ EF + S/CE + EH + S -+ CH -+ alk- R 2 -+ DetPG -+ alk- R 15 -+ prod uct/enantiomeric form or D) alk-PG -- EF + S/CE + EH + S -> alk- R - DetPG - alk- R 2 -+ 20 prod uct/enantiomeric form.
2. The process as claimed in claim 1, wherein the processes C) and D) are employed. 25
3. The process as claimed in claim 1 or 2, wherein compounds of the formula (111) X' -R 2 (1ll) 30 are used where X 1 is Cl, Br, I, OMs or OTs.
4. The process as claimed in any of claims 1 to 3, wherein compounds 35 of the formula (Ill) X' - R 2 (ill) are used where 74 X 1 is Cl, Br or l.
5. The process as claimed in claims 1 to 4, wherein a compound of the 5 formula (1) 0 0 R1 R2 is prepared where: R 1 is 10 R4 R4 R3 R in g A ON N5 (CH 2 )n R5 where 15 ring A is phenyl, 5-12 membered heteroaromatic ring which may contain from one or more heteroatoms from the group of N, 0 and S, fused/bicyclic 8 to 14 membered aromatic ring, (C3-C8)-cycloalkyl; R 3 is H, CF3, (C1-C6)-alkyl, (C 3 -C 8 )-cycloalkyl, phenyl; 20 R 4 , R 5 are H, F, Br, CF3, OCF 3 , (C1-C6)-alkyl, O-(C1-C6)-alkyl; n is from 1 to 2 and 25 R2 is (C1-C8)-alkyl where one or more CH2 groups in the alkyl groups may be replaced by 0, CO, S, SO or SO 2 , and alkyl may be one to trisubstituted by F, Cl, Br, CF 3 , CN, N02, NHAc, NHBoc, NH-CO C(CH 3 ) 3 , hydroxyl, OCF3, O-(C1-C6)-alkyl, COOH, CO-benzoxy, CO-O(C1-C6)-alkyl, tetrazole, thiazolidine-2,4-dione, indole and 30 (C6-C1o)-aryl, where thiazolidine-2,4-dione and aryl may in turn be substituted by F, Cl, Br, CF3, CN, NO 2 , NHAc, NHTs, NHBoc, NHCbz, NH-CO-C(CH3)3, hydroxyl, OCF3, 0-(C1-C6)-alkyl, COOH, 75 CO-benzoxy, CO-O(C1-C6)-alkyl, (C1-C6)-alkyl, 0-(C1-C6)-alkyl or tetrazole.
6. The process as claimed in any of claims 1 to 5, wherein a compound 5 of the formula (1) RI R2 (I) is prepared where: R 1 is 10 R4 R3 Ring A N (CH 2 )n R5 where 15 ring A is phenyl; R 3 is (C1-C4)-alkyl; R 4 , R 5 are H, (C1-C4)-alkyl, 0-(C1-C4)-alkyl; 20 n is 1 and R2 is (C1-C8)-alkyl where one or more CH 2 groups in the alkyl groups may be replaced by 0, CO, S, SO or S02 and alkyl may be one to 25 trisubstituted by F, Cl, Br, CF3, CN, NO 2 , NHAc, NHBoc, NH-CO C(CH 3 )3, hydroxyl, OCF 3 , 0-(C1-C6)-alkyl, COOH, CO-benzoxy, CO-O(C1-C6)-alkyl, tetrazole, thiazolidine-2,4-dione, indole and (C6-C10)-aryl, where thiazolidine-2-4-dione and aryl may in turn be substituted by F, Cl, Br, CF 3 , CN, NO 2 , NHAc, NHTs, NHBoc, 30 NHCbz, NH-CO-C(CH3)3, hydroxyl, OCF3, O-(C1-C6)-alkyl, COOH, CO-benzoxy, CO-O(C1-C6)-alkyl, (C1-C6)-alkyl, O-(C1-C6)-alkyl or tetrazole. 76
7. A process for preparing a chiral, non-racemic compound of the formula I substantially as hereinbefore described with reference to any one of the examples of the description numbered 1 to 80. SANOFI-AVENTIS DEUTSCHLAND GMBH WATERMARK PATENT & TRADEMARK ATTORNEYS P25875AU00
AU2004215674A 2003-02-27 2004-02-19 Method for producing the enantiomeric forms of cis 1,3-cyclohexanediol derivatives Ceased AU2004215674B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10308350A DE10308350B4 (en) 2003-02-27 2003-02-27 Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives
DE10308350.2 2003-02-27
PCT/EP2004/001580 WO2004076390A1 (en) 2003-02-27 2004-02-19 Method for producing the enantiomeric forms of cis 1,3-cyclohexanediol derivatives

Publications (2)

Publication Number Publication Date
AU2004215674A1 AU2004215674A1 (en) 2004-09-10
AU2004215674B2 true AU2004215674B2 (en) 2010-02-04

Family

ID=32863920

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004215674A Ceased AU2004215674B2 (en) 2003-02-27 2004-02-19 Method for producing the enantiomeric forms of cis 1,3-cyclohexanediol derivatives

Country Status (25)

Country Link
EP (1) EP1599433B1 (en)
JP (1) JP2006519001A (en)
KR (1) KR20050107469A (en)
CN (1) CN100572348C (en)
AR (1) AR044501A1 (en)
AT (1) ATE347543T1 (en)
AU (1) AU2004215674B2 (en)
BR (1) BRPI0407844A (en)
CA (1) CA2516623A1 (en)
CO (1) CO5690547A2 (en)
CY (1) CY1106454T1 (en)
DE (2) DE10308350B4 (en)
DK (1) DK1599433T3 (en)
ES (1) ES2278305T3 (en)
HK (1) HK1088889A1 (en)
IL (1) IL170310A (en)
MX (1) MXPA05009053A (en)
NO (1) NO20054456L (en)
NZ (1) NZ542025A (en)
PL (1) PL377812A1 (en)
PT (1) PT1599433E (en)
RU (1) RU2372319C2 (en)
TW (1) TWI331138B (en)
WO (1) WO2004076390A1 (en)
ZA (1) ZA200505760B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004038403B4 (en) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Process for preparing the enantiomeric forms of cis-configured 3-hydroxycyclohexanecarboxylic acid derivatives
DE102004040736B4 (en) * 2004-08-23 2007-01-11 Sanofi-Aventis Deutschland Gmbh Process for the preparation of Diarylcycloalkylderivaten
CN101381302B (en) * 2007-09-07 2013-04-03 上海睿智化学研究有限公司 2-bromomethyl-6-methyl benzoyl chloride/bromium and preparation method thereof
WO2009142184A1 (en) * 2008-05-21 2009-11-26 大正製薬株式会社 Method of producing bicyclo[3.1.0]hexane derivative using enzyme
CN110446495B (en) 2017-02-17 2023-09-05 特维娜有限公司 Delta opioid receptor modulating compounds containing 7-membered aza heterocycles and methods of use and preparation thereof
WO2023070605A1 (en) * 2021-10-29 2023-05-04 Trevena, Inc. Methods of preparing 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds
CN114891838B (en) * 2022-04-29 2023-09-08 株洲壹诺生物技术有限公司 Synthesis method of dorzolamide hydrochloride intermediate (S) -3- (2-thiophenyl) -butyric acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064876A1 (en) * 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
WO2003020269A1 (en) * 2001-08-31 2003-03-13 Aventis Pharma Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10004926A1 (en) * 2000-02-04 2001-08-09 Gruenenthal Gmbh Process for the enzymatic resolution of aminomethyl aryl cyclohexanol derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064876A1 (en) * 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
WO2003020269A1 (en) * 2001-08-31 2003-03-13 Aventis Pharma Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators

Also Published As

Publication number Publication date
DE10308350B4 (en) 2006-06-01
PL377812A1 (en) 2006-02-20
MXPA05009053A (en) 2005-10-19
CO5690547A2 (en) 2006-10-31
EP1599433B1 (en) 2006-12-06
AU2004215674A1 (en) 2004-09-10
HK1088889A1 (en) 2006-11-17
CY1106454T1 (en) 2011-10-12
DE10308350A1 (en) 2004-09-16
ATE347543T1 (en) 2006-12-15
PT1599433E (en) 2007-02-28
WO2004076390A1 (en) 2004-09-10
TWI331138B (en) 2010-10-01
AR044501A1 (en) 2005-09-14
TW200508392A (en) 2005-03-01
NO20054456L (en) 2005-09-26
RU2005129993A (en) 2006-01-27
NZ542025A (en) 2009-03-31
CN1753855A (en) 2006-03-29
RU2372319C2 (en) 2009-11-10
IL170310A (en) 2010-06-16
CN100572348C (en) 2009-12-23
ES2278305T3 (en) 2007-08-01
JP2006519001A (en) 2006-08-24
DK1599433T3 (en) 2007-04-16
EP1599433A1 (en) 2005-11-30
DE502004002234D1 (en) 2007-01-18
CA2516623A1 (en) 2004-09-10
ZA200505760B (en) 2006-05-31
BRPI0407844A (en) 2006-02-14
KR20050107469A (en) 2005-11-11

Similar Documents

Publication Publication Date Title
IL170310A (en) Method for producing the enantiomeric forms of cis 1,3-cyclohexanediol
EP1805316B1 (en) Process for the preparation of the enantiomeric forms of cis-3-hydroxycyclohexane carboxylic acid derivatives employing hydrolases
US20040209931A1 (en) Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives
JP2000509254A (en) Enzymatic methods for the stereoselective preparation of therapeutic amides
EP1587943A1 (en) Method for preparing a (r)- or (s)- form of n-(2,6-dimethyl phenyl) alanine and a counter enantiomeric form of n-(2,6-dimethyl phenyl) alanine ester thereto using enzyme
AU2005276642B2 (en) Method for the production of diarylcycloalkyl derivatives
JP6287528B2 (en) Method for producing optically active 3,3-difluorolactic acid derivative
EP0435293B1 (en) Methods of producing optically active hydroxyesters
KR20070076549A (en) Processes for the preparations of optically active cyclopentenones and cyclopentenones prepared therefrom
JPH08242872A (en) Method for enzyme acylation of alcohol using alkoxyvinyl acetate by eater interchange
JP3010382B2 (en) Method for producing (R) -2-propoxybenzene derivative
EP0683236B1 (en) Enzymatic process for the preparation of optical active tetralin-derivatives
WO2006009338A1 (en) Process for preparing chiral substituted carboxylic acid
WO2009147479A2 (en) Esterification process of prostaglandins and analogues thereof
EP0893508A2 (en) A new method for producing oxodicyclopentadiene

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH

Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired